Subject Index

A

ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
***N*-Acetylcysteine,** combined with ifosfamide in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group trial, 431
Acidic conditions, potentiation of cytotoxicity of zinostatin under, in vitro and in vivo, 247
Acivicin, phase II trial of, in malignant mesothelioma, 545
Aclarubicin
phase II evaluation of, in refractory multiple myeloma: a Southeastern Cancer Study Group trial, 773
phase II study of, in non-small cell lung cancer, 323
Active control studies, treatment evaluation in, 1061
Adenocarcinoma *see* Cancer, adenocarcinoma
Adjunctive chemotherapy, lack of benefit of, in stage I malignant melanoma: a Southwest Oncology Group study, 643
Adrenocortical cancer *see* Cancer, adrenocortical
Adverse effects, animals
acute myocardial effects of mitoxantrone in the rabbit, 529
effects of mitoxantrone and doxorubicin on energy metabolism of the rat heart, 361
experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes, 267
hematopoietic effects of TCNU in mice, 837
Adverse effects, man
acute laryngeal edema after single-dose irradiation and doxorubicin, 1322
acute thyroiditis as a complication of chemotherapy administration through a Hickman catheter, 788
allergy-induced hepatic toxicity associated with dacarbazine, 219
alprazolam for phobic nausea and vomiting related to cancer chemotherapy, 549
cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies, 609
cardiotoxicity of 5-fluorouracil, 733
chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity, 283
clonidine for anticipatory nausea and vomiting: a pilot study examining dose-toxicity relationships and potential for further study, 409
continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial, 309
continuous subcutaneous infusion of metoclopramide for treatment of narcotic bowel syndrome, 1121
cyclophosphamide hypersensitivity and cross-reactivity with chlorambucil, 1323
drug eruption localized to previously irradiated skin, 668
effectiveness of scalp cooling in reducing alopecia caused by epirubicin treatment of advanced breast cancer, 913
efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions, 979
hexamethylene bisacetamide-induced cutaneous vasculitis, 471
Hickman catheter clots: a common occurrence despite daily heparin flushing, 651
high-dose (200 mg/m^2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients, 669
ifosfamide-induced subclinical tubular nephrotoxicity despite mesna, 127
ifosfamide/mesna and hematuria, 1124
inadequacy of predicted creatinine clearance as guide to chemotherapy, 1067
intraocular inflammation from accidental instillation of doxorubicin, 221
local neurotoxicity after intra-arterial cisplatin in head and neck cancer, 257
mitoxantrone extravasation injury, 992
pulmonary toxicity of lomustine, 786
randomized, double-blind, cross-over study comparing prochlorperazine and lorazepam with high-dose metoclopramide and lorazepam for the control of emesis in patients receiving cytotoxic chemotherapy, 1007
respiratory dyskinesia due to antiemetic therapy in a cancer patient, 415
reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for ovarian carcinoma, 1324
rhabdomyolysis associated with high-dose cytarabine, 1325
severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma, 1122
sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy, 103
synthetic enkephalin analog in the treatment of cancer chemotherapy-induced vomiting, 665
transient nephrogenic diabetes insipidus following high-dose cyclophosphamide chemotherapy and autologous bone marrow transplantation, 220
unexpected toxicity encountered in the National Wilms' Tumor Study, 993
unusual skin reaction to echinomycin, 433
weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer, 253
Aerodigestive cancer *see* Cancer, aerodigestive
Age, influence of, on treatment outcome in small cell carcinoma of the lung, 291
AIDS-associated Kaposi's sarcoma, phase II study of oral idarubicin in patients with, 775
Alkylating agents
combined with methotrexate and 5-fluorouracil, compared to 10-ethyl-10-deaza-aminopterin, against advanced metastatic disease in murine tumor models, 727
high-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
Alprazolam, for phobic nausea and vomiting related to cancer chemotherapy, 549
Aminothiadiazole, phase II trial of, in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council trial, 649

Amsacrine
combined with cytarabine, prolonged unmaintained remission after intensive consolidation therapy with, in adult acute nonlymphocytic leukemia, 137
combined with diaziquone, in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study, 879
combined with high-dose busulfan and autologous bone marrow rescue in patients with acute myeloid leukemia in first remission, 552
combined with high-dose cytarabine, phase II study of, for resistant acute myelogenous leukemia, 881
continuous-infusion, in patients with refractory acute myelogenous leukemia, 1113
effect of, on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy, 479
Anaxirone, phase II trial of, in advanced non-small cell lung cancer, 539
Androgen therapy, in the treatment of refractory epithelial ovarian cancer, 537
Animal experiments *see also* Adverse effects, animals; Tumor systems, animals, distribution of clomesone in mice, 1135
Anthracycline-naive advanced breast cancer patients, phase II study of idarubicin given orally in the treatment of, 451
APUD tumors *see* Cancer, thyroid
Ara-CTP, effect of amsacrine on cellular pharmacology of, in human leukemia cells during high-dose cytarabine therapy, 479
1-β-D-Arabinofuranosyl-2-amino-1,4(2*H*)-4-iminopyrimidine, evaluation of antitumor activity of, in murine tumors, 441
Azacitidine
biochemistry of: a review, 959
10 years later, 737

B

Baker's antifol, phase II trial of, in advanced pancreatic cancer, 865
Benzisoquinolinedione, phase I clinical investigation of, 1165
Bisantrene
activity of, in refractory lymphoma, 631
phase II study of, in advanced renal cell carcinoma, 331
phase II trial of, in hepatocellular carcinoma: a Southwest Oncology Group study, 1101
Bladder cancer *see* Cancer, bladder
Bleomycin
combined with carboplatin and etoposide for treatment of stage IIC seminoma complicated by acute renal failure, 1123
combined with doxorubicin, vinblastine, and dacarbazine (ABVD); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
combined with vinblastine, phase II study of, in advanced ovarian cancer, 335
combined with cyclophosphamide and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients, 421
reduced dose of, combined with etoposide and cisplatin, treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with, 655
in temperature-sensitive liposomes, combined with local hyperthermia, selective treatment of metastatic lymph nodes with, 1053
transnodal cancer chemotherapy for metastatic lymph nodes in rats, 235
Bone marrow transplantation
autologous, combined with high-dose busulfan and amsacrine, in patients with acute myeloid leukemia in first remission, 552
autologous, combined with high-dose carmustine for the adjuvant treatment of high-grade gliomas of the central nervous system, 183
autologous, combined with high-dose cyclophosphamide chemotherapy, transient nephrogenic diabetes insipidus following, 220
autologous, combined with high-dose etoposide, phase II treatment of central nervous system gliomas with, 759
autologous, following high-dose dimethylbusulfan, phase I study of, in patients with advanced malignancy, 101
autologous, for ovarian carcinoma, reversible central nervous system toxicity associated with high-dose chlorambucil in, 1324
autologous, high-dose combination alkylating agent preparative regimen with: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
cryopreserved autologous, combined with high-dose iv thiotepa, for therapy of refractory cancer, 689
preceded by total-body irradiation and high-dose teniposide for patients with relapsed acute lymphoblastic leukemia: a pilot study, 645
Brain cancer *see* Cancer, central nervous system
Breast cancer *see* Cancer, breast
Buserelin, compared to the antiprogestin mifepristone (RU 486), the progestin megestrol acetate, and ovariectomy in the treatment of rat mammary tumors, 1021
Busulfan, high-dose, combined with amsacrine and autologous bone marrow rescue in patients with acute myeloid leukemia in first remission, 552

C

CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil), multiple drug intensification after induction with, in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial, 1271
Camptothecin, action of, on tumor cells, and disposition in mice, 341
Cancer *see also* Leukemia
adenocarcinoma of unknown primary origin, combination chemotherapy in the treatment of, 605
adrenocortical, cisplatin-based treatment of, 222
aerodigestive, advanced upper, phase II study of carmustine in, 781
bladder
high-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for, 915
T_2 and T_3, cisplatin as a first-line treatment in, 1285
transitional cell, phase II study of teniposide in: a Southwest Oncology Group study, 1307
breast
advanced, chemoendocrine therapy with prolonged estrogen priming in: endocrine pharmacokinetics and toxicity, 283
advanced, effectiveness of scalp cooling in reducing alopecia caused by epirubicin treatment of, 913
advanced, mitomycin and mitoxantrone in previously treated patients with, 191

advanced, oral versus im administration of high-dose medroxyprogesterone acetate in pretreated patients with, 1151
advanced, phase II evaluation of oral medroxyprogesterone acetate in: a Northern California Oncology Group study, 969
advanced, phase II evaluation of orally administered idarubicin in patients with, 1289
advanced, phase II study of peplomycin in, 777
advanced, phase II trial of 10-deaza-aminopterin in, 95
advanced, phase II trial of prednimustine as first-line chemotherapy in patients with, 1107
advanced postmenopausal, a multicenter study of trilostane: a new hormonal agent in, 1197
advanced, 1,2,4-triglycidylurazol in: a trial of the Phase II Study Group of the Association of Medical Oncology, German Cancer Society, 93
anthracycline-naive advanced, phase II study of idarubicin given orally in the treatment of, 451
endocrine-sensitive, oral gestrinone: a novel antiprogestin with no antitumor activity in, 1091
human cell lines in vitro, estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in, 901
human, doxorubicin distribution in, 1221
locally advanced, cell kinetics as a prognostic marker in, 375
meningioma preceding, 550
metastatic, clinical trial of plasma perfusion over immobilized staphylococcal protein A in, 411
metastatic, continuous 5-day infusion of vinblastine for percutaneous hepatic arterial chemotherapy of, 1001
metastatic, danazol in the treatment of women with, 875
metastatic, in postmenopausal women, second-line chemotherapy with tauromustine in: a phase II study, 987
metastatic, long duration of response with vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in: a pilot phase II study, 845
metastatic, multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in: a Southeastern Cancer Study Group phase II trial, 1271
metastatic or locally recurrent, medroxyprogesterone acetate in: variation in serum concentrations achieved with three commercially available preparations, 813
metastatic, percutaneous hepatic arterial infusion of cisplatin for, 313
metastatic, phase II study of iproplatin in, 1193
metastatic, phase II trial of a combination of doxorubicin and mitoxantrone in, 921
overview of randomized trials comparing radical mastectomy without radiotherapy against simple mastectomy with radiotherapy in, 7
overview of randomized trials of postoperative adjuvant radiotherapy in, 15
refractory metastatic, esorubicin in: a Northern California Oncology Group study, 427
response to tamoxifen and fluoxymesterone in a group of patients with disease recurrence after cessation of adjuvant tamoxifen, 685
carcinoid, malignant, phase II trial of rDNA alfa 2b interferon in patients with, 1265
central nervous system
glioma, phase II treatment of, with high-dose etoposide and autologous bone marrow transplantation, 759
glioma, therapeutic profile of the human line D-54 MG in athymic mice, 849
high grade gliomas, high-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of, 183
phase I trial of procarbazine as a 5-day continuous infusion in children with, 973
phase II trial of spirogermanium in: a Southwest Oncology Group study, 99
recurrent malignant gliomas, phase II study of spirohydantoin mustard for the treatment of, 1105
recurrent primary brain tumors, phase I–II study of eflornithine and mitoguazone combined in the treatment of, 459
cervical
advanced squamous cell, phase II trial of dichloromethotrexate in patients with, 1295
refractory adenocarcinoma, continuous-infusion vinblastine for treatment of, 547
squamous cell, teniposide in: a phase II trial of the Gynecologic Oncology Group, 873
colon
human cells, effect of hyperthermia on the sensitivity of, to mitoxantrone, 831
resistant to fluoropyrimidine chemotherapy, thymidylate synthase gene amplification in, 261
colorectal
adenocarcinoma, oral urea in the treatment of liver metastases from, 1119
advanced, 5-fluorouracil and cytarabine—ineffective treatment in: a Southeastern Cancer Study Group trial, 779
advanced, phase II clinical trial of tricyclic nucleoside phosphate for, 333
advanced, phase II study of esorubicin in patients with, who have received no prior chemotherapy: an Illinois Cancer Council trial, 765
advanced, phase II study of *N*-methylformamide in patients with, 541
advanced, phase II trial of aminothiadiazole in previously treated and untreated patients with: an Illinois Cancer Council trial, 649
advanced, phase II trial of ifosfamide and mesna in, 663
advanced, phase II trial of menogaril in patients with: an Illinois Cancer Council trial, 871
advanced, phase II trial of recombinant beta interferon in, 965
advanced, pilot trial of continuous-infusion 5-fluorouracil and weekly cisplatin in, 615
continuous-infusion cisplatin and bolus 5-fluorouracil in, 975
metastatic, high-dose human lymphoblastoid interferon in: clinical results and modification of biological responses, 39
metastatic, phase II study on oral *N*-methylformamide in, 1293
open-label phase II trial of recombinant beta interferon (IFN-β_{ser}) in patients with, 983
phase II study of fludarabine phosphate in previously untreated patients with: a Southwest Oncology Group study, 1319
phase II study of tiazofurin in: a National Cancer Institute of Canada study, 1297
phase II trial of oral methotrexate and dipyridamole in, 821
severe and toxic effects observed in treatment with high-

and low-dose leucovorin plus 5-fluorouracil for, 1122
toxic and therapeutic effects of weekly 5-fluorouracil combined with PALA in, 253
endometrial
advanced, phase II study of idarubicin in, 535
mitoxantrone for: a phase II trial of the Gynecologic Oncology Group, 217
recurrent or metastatic poorly differentiated adenocarcinoma, treatment of, with tamoxifen and medroxyprogesterone acetate, 327
esophageal, preliminary report on the treatment of, by intraluminal microwave hyperthermia and chemotherapy, 1013
gastric
advanced, phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in, 1301
FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
gastrointestinal tract, adenocarcinomas of upper, phase II trial of cisplatin and etoposide in, 329
head and neck
local neurotoxicity after intra-arterial cisplatin in, 257
locoregional previously untreated squamous, phase II trial of high-dose cytarabine and cisplatin in: a Piedmont Oncology Association study, 151
phase II trial of fludarabine phosphate in patients with, 1313
previously untreated squamous cell, phase II study of etoposide in, 321
recurrent and advanced, platinum analogs in: a Southwest Oncology Group and Wayne State University study, 723
recurrent squamous cell, phase II trial of tiazofurin in, 425
recurrent squamous cell, simultaneous cisplatin and 5-fluorouracil as second-line treatment of, 485
squamous cell, combination of mitomycin, vindesine, and cisplatin in the treatment of, 81
hepatocellular
advanced, phase II study of deoxydoxorubicin in patients with, 1117
controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in, 1213
phase II trial of bisantrene in: a Southwest Oncology Group study, 1101
hepatoma, phase II study of fludarabine phosphate in previously untreated patients with: a Southwest Oncology Group study, 1111
Hodgkin's disease
refractory to COPP and ABVD, lomustine, etoposide, vindesine, and dexamethasone (CEVD) in: a multicenter trial of the German Hodgkin Study Group, 1203
resistant, third-line chemotherapy for, with lomustine, etoposide, and methotrexate, 475
lung
advanced non-small cell, carboplatin or iproplatin in: a Cancer and Leukemia Group B study, 1049
advanced non-small cell, combination chemotherapy with ifosfamide, mitomycin, and cisplatin in, 851
advanced non-small cell, etoposide, ifosfamide, and cisplatin in the treatment of, 1311
advanced non-small cell, phase II study of isotretinoin in the treatment of, 1097
advanced non-small cell, phase II trial of anaxirone in, 539
advanced non-small cell, phase II trial of 4′-deoxydoxorubicin in, 861
advanced non-small cell, phase II trial of esorubicin in patients with, 783
advanced or recurrent non-small cell, phase II study of caracemide in, 1099
etoposide- and cisplatin-resistant small cell, cyclophosphamide, doxorubicin, and vincristine in, 941
extensive-disease small cell, phase II study of oral idarubicin in: testing new drugs may prejudice the results of standard treatment, 1227
extensive-disease small cell, phase II trial evaluating continuous infusion of etoposide, cisplatin, and hexamethylmelamine in, 575
extensive small cell, high-dose etoposide therapy for: a Cancer and Leukemia Group B study, 533
extensive small cell, phase II trial of mitoxantrone as first-line chemotherapy for, 1291
extensive, untreated non-small cell, phase II study of 5,6-dihydro-5-azacitidine in, 859
human cell lines, in vitro chemosensitivity of, 697
initially inoperable stage III M_0 non-small cell, pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in, 895
locally advanced non-small cell, concurrent cisplatin and etoposide with radiotherapy in, 681
metastatic small cell, phase II study of carboplatin in previously untreated patients with, 311
non-small cell, ifosfamide plus *N*-acetylcysteine in the treatment of: a Southeastern Cancer Study Group trial, 431
non-small cell, phase II study of aclarubicin in, 323
non-small cell, teniposide in the treatment of, 83
non-small cell, treatment of, with coumarin and cimetidine, 91
novel candidate for clinical evaluation in: preclinical toxicology studies of 4-ipomeanol, 1157
small cell, addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with, 61
small cell, high-dose cytarabine in, 417
small cell, identification of new drugs in: phase II agents first? 1131
small cell: influence of age on treatment outcome, 291
small cell, phase II study of lonidamine in patients with, 1283
stage III non-small cell, phase II trial of oral piritrexim (BW301U) in patients with, 763
lymphatic
human, perturbation of in vitro drug resistance in specimens of, by combinations of putative inhibitors of protein kinase C, 1239
human, selective enhancement by menadiol of in vitro drug activity in, 619
lymphoma
advanced, low-grade non-Hodgkin's, high-dose pulse chlorambucil in, 1029
advanced refractory, treatment of, with teniposide and lomustine, 215
advanced, salvage chemotherapy of, with investigational drugs: mitoguazone, gallium nitrate, and etoposide, 47
non-Hodgkin's, mitoxantrone in the treatment of patients with, 1209
non-Hodgkin's, salvage chemotherapy for, with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone, 639
refractory, activity of bisantrene in, 631
refractory non-Hodgkin's, cytarabine, cisplatin, and etopo-

side chemotherapy for, 187
refractory non-Hodgkin's, of unfavorable histology, treatment of, with teniposide, cytarabine, and cisplatin, 659
melanoma
advanced malignant, phase II study of dacarbazine, vindesine, and cisplatin combination chemotherapy in, 997
advanced malignant, phase II study of prednimustine in, 1315
advanced malignant, phase II study of the combination of carmustine and 6-thioguanine in, 429
advanced malignant, phase II study of the combination of vinblastine plus cisplatin administered by continuous 120-hour infusion for patients with, 769
advanced malignant, phase II trial of carboplatin in, 171
advanced, phase II trial of esorubicin in patients with, 325
disseminated malignant, phase II study of recombinant interferon-gamma in patients with, 843
malignant, combination chemotherapy and hormonal therapy in the treatment of, 465
malignant, phase II evaluation of spirogermanium in: a Southwest Oncology Group study, 985
malignant, phase II study of iv menogaril in patients with: a National Cancer Institute of Canada Clinical Trials Group study, 771
metastatic malignant, treatment of, with dacarbazine and cisplatin, 877
stage I malignant, lack of benefit of adjunctive chemotherapy in: a Southwest Oncology Group study, 643
use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against xenografts of, 297
mesothelioma
malignant, phase II trial of acivicin in, 545
malignant, phase II trial of mitomycin in, 857
malignant pleural, phase II trial of vindesine in, 205
myeloma
multiple, contribution of prednisone to the effectiveness of hexamethylmelamine in, 807
multiple, weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in, 981
refractory and relapsing multiple, phase II trial of diaziquone in patients with: a Southwest Oncology Group study, 1095
refractory multiple, phase II evaluation of aclarubicin in: a Southeastern Cancer Study Group trial, 773
ovarian
advanced, cisplatin plus etoposide as second-line treatment in, 790
advanced, phase II study of vinblastine and bleomycin in, 335
advanced, pilot study of cyclophosphamide plus carboplatin in, 199
epithelial, phase II study of mitoxantrone in, 627
mixed mesodermal, cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of, 1275
primary advanced, high-dose (200 mg/m^2) cisplatin-induced neurotoxicity in patients with, 669
refractory epithelial, androgen therapy in the treatment of, 537
reversible central nervous system toxicity associated with high-dose chlorambucil in autologous bone marrow transplantation for, 1324
role of hexamethylmelamine in the treatment of: where is the needle in the haystack? 666
stage III and IV epithelial, high-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with, 455
stage III–IV, second-line chemotherapy of: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin, 277
use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against xenografts of, 297
pancreatic
adenocarcinoma, ifosfamide plus 5-fluorouracil for treatment of, 1115
advanced, phase II trials of the single agents Baker's antifol, diaziquone, and epirubicin in, 865
malignant endocrine, treatment of, with human leukocyte interferon, 31
phase II evaluation of diaziquone in: a Southwest Oncology Group study, 1309
phase II trial of idarubicin in patients with, 657
unresectable adenocarcinoma, tamoxifen therapy in, 749
prostatic
advanced adenocarcinoma, phase II study of spirogermanium in: a Southwest Oncology Group study, 1305
gallium nitrate in: evaluation of antitumor activity and effects on bone turnover, 887
metastatic hormone-resistant, phase II evaluation of mitoguazone in: a Southeastern Cancer Study Group trial, 89
metastatic, phase II study of low-dose weekly epirubicin in: a European Organization for Research and Treatment of Cancer (EORTC) study, 1317
renal
metastatic adult, phase II trial of ifosfamide/mesna in, 1103
metastatic, phase II trial of esorubicin in the treatment of: a study of the Northern California Oncology Group, 767
renal cell
advanced, high-dose lymphoblastoid interferon in: an Eastern Cooperative Oncology Group study, 165
advanced, phase II studies of PCNU and bisantrene in, 331
advanced, phase II trial of streptozocin in the treatment of, 97
advanced, therapy for, with spirogermanium: a Southwest Oncology Group study, 207
evaluation of fludarabine phosphate in: a Southwest Oncology Group study, 543
metastasized, phase II trial of 1,2,4-triglycidylurazol in patients with, 209
metastatic, phase II study of teniposide in: a Southwest Oncology Group study, 1307
sarcoma
adult soft tissue, combination chemotherapy of, with a combination of doxorubicin and methotrexate, 1087
advanced bone, phase II study of recombinant alfa-2a interferon in patients with, 747
advanced, continuous venous infusion of doxorubicin in, 971
advanced nonosseous, phase II study of recombinant gamma-interferon in patients with, 211
advanced soft tissue, phase II trial of cisplatin and etoposide in children with: a report from the Italian Cooperative Rhabdomyosarcoma Group, 525
childhood rhabdomyosarcoma, drug accumulation and response of xenografts of, determined by frequency of administration of vincristine, 717
Kaposi's, AIDS-associated, phase II study of oral idarubicin

in patients with, 775
metastatic osteosarcoma, bleomycin, cyclophosphamide, and dactinomycin in: lack of tumor regression in previously treated patients, 421
metastatic soft tissue, phase II study of mitoxantrone in untreated and previously minimally treated patients with, 1109
recurrent or unresponsive soft tissue, in children, inefficacy of cisplatin and etoposide as salvage therapy for, 407
solid tumors
hammering away at, 115
malignant, phase II trial of ifosfamide in children with, 131
testicular
advanced germ cell, refractory to cisplatin, phase II trial of carboplatin in patients with, 197
advanced, refractory germ cell, carboplatin in: a phase II Eastern Cooperative Oncology Group study, 989
favorable-prognosis nonseminomatous germ cell, treatment of, with etoposide, cisplatin, and reduced dose of bleomycin, 655
refractory germ cell, phase II evaluation of iproplatin in: a Southeastern Cancer Study Group trial, 863
stage IIC seminoma complicated by acute renal failure, carboplatin, etoposide, and bleomycin for treatment of, 1123
transient tumor marker surge following chemotherapy of, 785
thyroid, phase II trial of etoposide in APUD tumors, 305
uterine
advanced and recurrent leiomyosarcoma, phase II trial of etoposide in the management of: a Gynecologic Oncology Group study, 0000
advanced or recurrent mixed mesodermal sarcomas, phase II trial of etoposide in the management of: a Gynecologic Oncology Group study, 661
vaginal, advanced or recurrent, phase II trial of etoposide in the management of: a Gynecologic Oncology Group study, 869
vulval, advanced or recurrent squamous cell, phase II trial of etoposide in the management of: a Gynecologic Oncology Group study, 1303
Cancer clinical trials
closing the loop: providing feedback on drug development, 1
generation of dose intensity-response data suggested for, 1125
identification of new drugs in small cell lung cancer: phase II agents first? 1131
patient accrual to, 557
paying for patient care in treatment research—who is responsible? 107
randomized, overviews of, 3
selection factors in: results from the Community Clinical Oncology Program Physician's Patient Log, 559
some thoughts on the future of clinical trials groups in cancer, 434
treatment evaluation in active control studies, 1061
CAP (cyclophosphamide, doxorubicin, and cisplatin), and chest irradiation, pilot study of, prior to thoracotomy in initially inoperable stage III M_0 non-small cell lung cancer, 895
Caracemide
phase I trial of, using bolus and infusion schedules, 349
phase II study of, in advanced or recurrent non-small cell lung cancer, 1099
Carbogen breathing, combined with Fluosol-DA, survey of the effect of adding, to treatment with various chemotherapeutic agents, 173
Carboplatin
in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study, 1049
in advanced, refractory germ cell neoplasms: a phase II Eastern Cooperative Oncology Group study, 989
combined with cyclophosphamide, pilot study of, in advanced ovarian carcinoma, 199
combined with etoposide and bleomycin, for treatment of stage IIC seminoma complicated by acute renal failure, 1123
pediatric phase I trial of: a Childrens Cancer Study Group report, 1039
pharmacokinetics of, after iv administration, 1231
phase II study of, in previously untreated patients with metastatic small cell lung carcinoma, 311
phase II trial of, in advanced malignant melanoma, 171
phase II trial of, in patients with advanced germ cell tumors refractory to cisplatin, 197
in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University study, 723
Carcinoid tumors *see* Cancer, carcinoid
Carmustine
combined with cyclophosphamide, cisplatin, and melphalan: high-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
combined with dacarbazine, cisplatin, and tamoxifen in the treatment of malignant melanoma, 465
combined with hydroxyurea and dacarbazine, as adjunctive chemotherapy in stage I malignant melanoma, lack of benefit of: a Southwest Oncology Group study, 643
combined with 6-thioguanine, phase II study of, in advanced malignant melanoma, 429
high-dose, combined with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system, 183
high-dose, immediate effects of, in man, and pharmacokinetics, 433
phase II study of, in advanced upper aerodigestive cancer, 781
Cell culture studies *see also* In vitro studies
cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin, 381
effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy, 479
effect of hyperthermia on the sensitivity of human colon carcinoma cells to mitoxantrone, 831
estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro, 901
in vitro chemosensitivity of human lung cancer cell lines, 697
interaction of etoposide and cisplatin in an in vitro tumor model, 673
media for LAK cell generation, 104
perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C, 1239
potentiation of cytotoxicity of zinostatin under acidic conditions in vitro and in vivo, 247
synergistic effect of recombinant interleukin-2 on the inhibi-

tion of growth of adenocarcinoma 755 by mitomycin, 567
verapamil reversal of vincristine resistance and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells, 353
Cell kinetics, as a prognostic marker in locally advanced breast cancer, 375
Central nervous system cancer *see* Cancer, central nervous system
Cervical cancer *see* Cancer, cervical
CEVD (lomustine, etoposide, vindesine, and dexamethasone), in Hodgkin's lymphoma refractory to COPP and ABVD: a multicenter trial of the German Hodgkin Study Group, 1203
Chemoendocrine therapy, with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity, 283
Chemotherapeutic agents
and FDA regulations: square pegs for round holes? 795
semiautomated colorimetric assay for in vitro screening of, 1141
Children *see also* Infants
with acute lymphoblastic leukemia, phase II study of idarubicin administered iv to, 855
with advanced soft tissue sarcoma, phase II trial of cisplatin and etoposide in: a report from the Italian Cooperative Rhabdomyosarcoma Group, 525
with central nervous system tumors, phase I trial of procarbazine as a 5-day continuous infusion in, 973
ifosfamide-induced subclinical tubular nephrotoxicity despite mesna, 127
iv melphalan in, 1277
with malignant solid tumors, phase II trial of ifosfamide in, 131
pediatric phase I trial of carboplatin: a Children's Cancer Study Group report, 1039
phase I study of iproplatin in: a Pediatric Oncology Group study, 87
with recurrent or unresponsive soft tissue sarcoma, inefficacy of cisplatin and etoposide as salvage therapy for, 407
with refractory leukemia, phase I trial of homoharringtonine in, 1245
with refractory leukemias, phase I trial of *N*-methylformamide in, 1299
scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration, 717
unexpected toxicity encountered in the National Wilms' Tumor Study, 993
Chlorambucil
cyclophosphamide hypersensitivity and cross-reactivity with, 1323
high-dose, in autologous bone marrow transplantation for ovarian carcinoma, reversible central nervous system toxicity associated with, 1324
high-dose, pulse, in advanced, low-grade non-Hodgkin's lymphoma, 1029
Cimetidine, combined with coumarin, treatment of non-small cell lung cancer with, 91
Circadian drug timing may be a critical factor in therapy, 1321
Cisplatin
administered by continuous 120-hour infusion, combined with vinblastine, phase II study of, for patients with advanced malignant melanoma, 769
-based treatment of adrenocortical carcinoma, 222
combined with cyclophosphamide and doxorubicin (CAP) and chest irradiation, pilot study of induction therapy with, prior to thoracotomy in initially inoperable stage III M_0 non-small cell lung cancer, 895
combined with cyclophosphamide, carmustine, and melphalan: high-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
combined with cytarabine and etoposide, for refractory non-Hodgkin's lymphoma, 187
combined with dacarbazine and vindesine in advanced malignant melanoma: a phase II study, 997
combined with dacarbazine, carmustine, and tamoxifen in the treatment of malignant melanoma, 465
combined with dacarbazine, treatment of metastatic malignant melanoma with, 877
combined with doxorubicin, a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent ovarian carcinoma after, 277
combined with doxorubicin and cyclophosphamide (PAC), in the treatment of mixed mesodermal tumor of the ovary, 1275
combined with doxorubicin, high-dose intensity, circadian-timed, as adjuvant chemotherapy for bladder cancer, 915
combined with etoposide and ifosfamide in the treatment of advanced non-small cell lung cancer, 1311
combined with etoposide and reduced dose of bleomycin, treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with, 655
combined with etoposide as second-line treatment in advanced ovarian carcinoma, 790
combined with etoposide, inefficacy of, as salvage therapy for children with recurrent or unresponsive soft tissue sarcoma, 407
combined with etoposide, phase II trial of, in adenocarcinomas of the upper gastrointestinal tract, 329
combined with etoposide, phase II trial of, in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group, 525
combined with etoposide, with concurrent radiotherapy in locally advanced non-small cell lung cancer, 681
combined with 5-fluorouracil and doxorubicin (FAP), phase II trial of, in advanced gastric carcinoma, 1301
combined with hexamethylmelamine and a continuous infusion of etoposide, phase II trial of, in extensive-disease small cell carcinoma of the lung, 575
combined with high-dose cytarabine, phase II trial of, in locoregional previously untreated squamous carcinoma of the head and neck: a Piedmont Oncology Association study, 151
combined with ifosfamide and mitomycin in advanced non-small cell lung cancer, 851
combined with mitomycin and vindesine, in the treatment of head and neck squamous cell carcinoma, 81
combined with mitoxantrone, etoposide, and prednisolone, salvage chemotherapy for non-Hodgkin's lymphoma with, 639
combined with simultaneous 5-fluorouracil as second-line treatment of head and neck cancer, 485
combined with teniposide and cytarabine in the treatment of refractory non-Hodgkin's lymphomas of unfavorable histology, 659
continuous infusion of, combined with bolus 5-fluorouracil in colorectal carcinomas, 975

effects of intralesional versus ip administration of, on squamous cell carcinoma of mice, 825
efficacy of continuous high-dose metoclopramide in patients receiving daily infusions of, 979
and etoposide-resistant small cell lung cancer, cyclophosphamide, doxorubicin, and vincristine in, 941
as a first-line treatment in T_2 and T_3 bladder carcinoma, 1285
high-dose (200 mg/m²), neurotoxicity induced by, in primary advanced ovarian cancer patients, 669
interaction with etoposide, in an in vitro tumor model, 673
intra-arterial, in head and neck cancer, local neurotoxicity after, 257
percutaneous hepatic arterial infusion of, for metastatic breast cancer, 313
phase II trial of carboplatin in patients with advanced germ cell tumors refractory to, 197
reappraisal of some dosage adjustment guidelines, 229
weekly, combined with doxorubicin, high-dose-intensity regimen of, in the treatment of patients with stage III and IV epithelial ovarian carcinoma, 455
weekly, combined with prolonged continuous-infusion 5-fluorouracil in advanced colorectal cancer, pilot trial of, 615

Clomesone, distribution of, in mice, 1135

Clonidine, for anticipatory nausea and vomiting: a pilot study examining dose-toxicity relationships and potential for further study, 409

Closing the loop: providing feedback on drug development, 1

Colon cancer *see* Cancer, colon

Colorectal cancer *see* Cancer, colorectal

Colorimetric assay, semiautomated, for in vitro screening of anticancer compounds, 1141

COMF (cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil), in the treatment of adenocarcinoma of unknown primary origin, 605

COPP (cyclophosphamide, vincristine, procarbazine, and prednisone); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203

Coumarin, combined with cimetidine, treatment of non-small cell lung cancer with, 91

Creatinine clearance, predicted, inadequacy of, as guide to chemotherapy, 1067

Cyclophosphamide
combined with bleomycin and dactinomycin, in metastatic osteosarcoma: lack of tumor regression in previously treated patients, 421
combined with carboplatin, pilot study of, in advanced ovarian carcinoma, 199
combined with cisplatin and doxorubicin (PAC) in the treatment of mixed mesodermal tumor of the ovary, 1275
combined with cisplatin, carmustine, and melphalan: high-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
combined with doxorubicin and cisplatin (CAP) and chest irradiation, pilot study of induction therapy with, prior to thoracotomy in initially inoperable stage III M_0 non-small cell lung cancer, 895
combined with doxorubicin and 5-fluorouracil (CAF), multiple drug intensification after induction with, in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial, 1271
combined with doxorubicin and vincristine, addition of etoposide to, for remission induction and survival in patients with small cell lung cancer, 61
combined with doxorubicin and vincristine in etoposide- and cisplatin-resistant small cell lung cancer, 941
combined with vincristine, methotrexate, and 5-fluorouracil (COMF), in the treatment of adenocarcinoma of unknown primary origin, 605
combined with vincristine, procarbazine, and prednisone (COPP); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
high-dose, combined with autologous bone marrow transplantation, transient nephrogenic diabetes insipidus following, 220
hypersensitivity and cross-reactivity with chlorambucil, 1323
and methotrexate, interactions of, with pharmacokinetics of 5-fluorouracil in an animal model, 1267
therapeutic profile of the human glioma line D-54 MG in athymic mice, 849
weekly, combined with alternate-day prednisone: an effective secondary therapy in multiple myeloma, 981

Cytarabine
combined with amsacrine, prolonged unmaintained remission after intensive consolidation therapy with, in adult acute nonlymphocytic leukemia, 137
combined with cisplatin and etoposide, for refractory non-Hodgkin's lymphoma, 187
combined with daunorubicin and 6-thioguanine, influence of sequencing of, on the outcome of therapy in acute myelogenous leukemia: a randomized trial, 571
combined with etoposide, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age, 201
combined with 5-fluorouracil—ineffective treatment in advanced colorectal carcinoma: a Southeastern Cancer Study Group trial, 779
combined with mitoxantrone, phase II study of, in acute myeloid leukemia, 161
combined with teniposide and cisplatin in the treatment of refractory non-Hodgkin's lymphomas of unfavorable histology, 659
entrapped in the presence of hydrochloric acid, multivesicular liposomes containing, for intracavitary chemotherapy, 705
high-dose, combined with amsacrine, phase II study of, for resistant acute myelogenous leukemia, 881
high-dose, combined with cisplatin, phase II trial of, in locoregional previously untreated squamous carcinoma of the head and neck: a Piedmont Oncology Association study, 151
high-dose, effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during therapy with, 479
high-dose, in small cell lung cancer, 417
high-dose, rhabdomyolysis associated with, 1325
multivesicular liposomes containing, for slow-release sc administration, 447

D

Dacarbazine
allergy-induced hepatic toxicity associated with, 219
combined with carmustine and hydroxyurea, as adjunctive chemotherapy in stage I malignant melanoma, lack of benefit of: a Southwest Oncology Group study, 643
combined with cisplatin, carmustine, and tamoxifen in the

treatment of malignant melanoma, 465
combined with cisplatin, treatment of metastatic malignant melanoma with, 877
combined with doxorubicin, bleomycin, and vinblastine (ABVD); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
combined with vindesine and cisplatin in advanced malignant melanoma: a phase II study, 997
experimental, antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes, 267
Dactinomycin
combined with bleomycin and cyclophosphamide, in metastatic osteosarcoma: lack of tumor regression in previously treated patients, 421
combined with vincristine: unexpected toxicity encountered in the National Wilms' Tumor Study, 993
Danazol, in the treatment of women with metastatic breast cancer, 875
Daunorubicin
combined with cytarabine and 6-thioguanine, influence of sequencing of, on the outcome of therapy in acute myelogenous leukemia: a randomized trial, 571
synergy between low-dose chemotherapy and immunotherapy in mouse L1210 leukemia, 241
10-Deaza-aminopterin, phase II trial of, in advanced breast cancer, 95
Delirium and severe sedation, in patients with terminal cancer, 787
Deoxydoxorubicin, phase II study of, in patients with advanced liver cancer, 1117
4′-Deoxydoxorubicin, phase II trial of, in advanced non-small cell lung cancer, 861
Dexamethasone, combined with lomustine, etoposide, and vindesine (CEVD), in Hodgkin's lymphoma refractory to COPP and ABVD: a multicenter trial of the German Hodgkin Study Group, 1203
Diaziquone
combined with amsacrine, in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study, 879
continuous-infusion, in acute myeloid leukemia: a Southeastern Cancer Study Group trial, 309
continuous-infusion, phase II study of, in relapsed/refractory acute nonlymphocytic leukemia, 755
phase II evaluation of, in pancreatic carcinoma: a Southwest Oncology Group study, 1309
phase II trial of, in advanced pancreatic cancer, 865
phase II trial of, in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group study, 1095
Dichloromethotrexate, phase II trial of, in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, 1295
5,6-Dihydro-5-azacitidine, phase II study of, in extensive, untreated non-small cell lung cancer, 859
Dimethylbusulfan, high-dose, followed by autologous bone marrow transplantation, phase I study of, in patients with advanced malignancy, 101
Dipyridamole, combined with oral methotrexate, phase II trial of, in colorectal carcinoma, 821
Dosage
dose intensity-response data generation suggested for drug studies, 1125
of 11 chemotherapy agents, actual versus ideal weight in the calculation of surface area: effects on, 907
reappraisal of some dosage adjustment guidelines, 229
Doxorubicin
combined with bleomycin, vinblastine, and dacarbazine (ABVD); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
combined with cisplatin, a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent ovarian carcinoma after, 277
combined with cisplatin and cyclophosphamide (PAC), in the treatment of mixed mesodermal tumor of the ovary, 1275
combined with cisplatin, high-dose intensity, circadian-timed, as adjuvant chemotherapy for bladder cancer, 915
combined with cyclophosphamide and cisplatin (CAP) and chest irradiation, pilot study of induction therapy with, prior to thoracotomy in initially inoperable stage III M_0 non-small cell lung cancer, 895
combined with cyclophosphamide and 5-fluorouracil (CAF), multiple drug intensification after induction with, in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial, 1271
combined with cyclophosphamide and vincristine, addition of etoposide to, for remission induction and survival in patients with small cell lung cancer, 61
combined with cyclophosphamide and vincristine, in etoposide and cisplatin-resistant small cell lung cancer, 941
combined with etoposide, cytarabine, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age, 201
combined with 5-fluorouracil and cisplatin (FAP), phase II trial of, in advanced gastric carcinoma, 1301
combined with 5-fluorouracil and mitomycin (FAM) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
combined with methotrexate, in adult soft tissue sarcoma, 1087
combined with mitoxantrone, phase II trial of, in metastatic breast cancer, 921
combined with single-dose irradiation, acute laryngeal edema after, 1322
combined with tamoxifen, compared to doxorubicin alone, controlled clinical trial of, in hepatocellular carcinoma, 1213
compared to mitoxantrone, for effects on energy metabolism of the rat heart, 361
continuous venous infusion of, in advanced sarcomas, 971
cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to, 195
distribution of, in human breast cancer, 1221
intraocular inflammation from accidental instillation of, 221
linked to pyran copolymer via the side chain of the drug, increased therapeutic efficacy and reduced toxicity of, 367
reappraisal of some dosage adjustment guidelines, 229
weekly, combined with cisplatin, high-dose-intensity regimen of, in the treatment of patients with stage III and IV epithelial ovarian carcinoma, 455
Drug resistance
cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin, 195
cyclophosphamide, doxorubicin, and vincristine in etoposide and cisplatin-resistant small cell lung cancer, 941
facilitation of emergence of multidrug-resistant state by alteration of tumor environment: implications from compet-

itive ecology models, 1093
perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C, 1239
selective enhancement by menadiol of in vitro drug activity in human lymphatic neoplasms, 619
thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy, 261
verapamil reversal of vincristine resistance and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells, 353
Drug scheduling
demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia, 581
timing may be a critical factor in drug therapy, 1321

E

Echinomycin
phase I study of, 1217
unusual skin reaction to, 433
Eflornithine, combined with mitoguazone in the treatment of recurrent primary brain tumors, phase I–II study of, 459
Endometrial cancer *see* Cancer, endometrial
Enkephalin analog, synthetic, in the treatment of cancer chemotherapy-induced vomiting, 665
Epirubicin
effectiveness of scalp cooling in reducing alopecia caused by treatment of advanced breast cancer with, 913
given on a weekly schedule, phase I study of, 273
low-dose weekly, phase II study of, in metastatic prostate cancer: a European Organization for Research and Treatment of Cancer (EORTC) study, 1317
phase II trial of, in advanced pancreatic cancer, 865
Esophageal cancer *see* Cancer, esophageal
Esorubicin
phase II study of, in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council trial, 765
phase II trial of, in patients with advanced melanoma, 325
phase II trial of, in patients with advanced non-small cell lung cancer, 783
phase II trial of, in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group, 767
in refractory metastatic carcinoma of the breast: a Northern California Oncology Group study, 427
Estrogen-nitrosourea conjugates, estrogen receptor-binding affinity and cytotoxic activity of three new, in human breast cancer cell lines in vitro, 901
Estrogen priming, prolonged, chemoendocrine therapy with, in advanced breast cancer: endocrine pharmacokinetics and toxicity, 283
10-Ethyl-10-deaza-aminopterin, compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models, 727
7-Ethylcamptothecin, action of, on tumor cells, and disposition in mice, 341
Etoposide
added to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer, 61
and cisplatin-resistant small cell lung cancer, cyclophosphamide, doxorubicin, and vincristine in, 941
combined with carboplatin and bleomycin, for treatment of stage IIC seminoma complicated by acute renal failure, 1123
combined with cisplatin and reduced dose of bleomycin, treatment of favorable-prognosis nonseminomatous testicular germ cell tumors with, 655
combined with cisplatin as second-line treatment in advanced ovarian carcinoma, 790
combined with cisplatin, inefficacy of, as salvage therapy for children with recurrent or unresponsive soft tissue sarcoma, 407
combined with cisplatin, phase II trial of, in adenocarcinomas of the upper gastrointestinal tract, 329
combined with cisplatin, phase II trial of, in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group, 525
combined with cisplatin, with concurrent radiotherapy in locally advanced non-small cell lung cancer, 681
combined with cytarabine and cisplatin, for refractory non-Hodgkin's lymphoma, 187
combined with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age, 201
combined with ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer, 1309
combined with lomustine and methotrexate, third-line chemotherapy for resistant Hodgkin's disease with, 475
combined with lomustine, vindesine, and dexamethasone (CEVD), in Hodgkin's lymphoma refractory to COPP and ABVD: a multicenter trial of the German Hodgkin Study Group, 1203
combined with mitoguazone and gallium nitrate, salvage chemotherapy of advanced lymphoma with, 47
combined with mitomycin, sudden dyspnea occurring 24 hours after, 103
combined with mitoxantrone, cisplatin, and prednisolone, salvage chemotherapy for non-Hodgkin's lymphoma with, 639
continuous infusion of, combined with cisplatin and hexamethylmelamine, phase II trial of, in extensive-disease small cell carcinoma of the lung, 575
generation of dose intensity-response data suggested for drug studies, 1125
high-dose, combined with autologous bone marrow transplantation, phase II treatment of central nervous system gliomas with, 759
high-dose, therapy for extensive small cell lung cancer with: a Cancer and Leukemia Group B study, 533
interaction with cisplatin, in an in vitro tumor model, 673
phase II study of, in previously untreated squamous cell carcinoma of the head and neck, 321
phase II trial of, in APUD tumors, 305
phase II trial of, in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, 1303
phase II trial of, in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study, 661
phase II trial of, in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group study, 869

F

FAM (5-fluorouracil, doxorubicin, and mitomycin), combined with triazinate (FAM-T) in gastric carcinoma: a com-

bined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
FAM-T (5-fluorouracil, doxorubicin, mitomycin, and triazinate), in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
FAP (5-fluorouracil, doxorubicin, and cisplatin), phase II trial of, in advanced gastric carcinoma, 1301
FDA regulations and antineoplastic agents: square pegs for round holes? 795
Feedback on drug development, closing the loop: providing, 1
Floxuridine, combined with 5-fluorouracil, enhancement of cytotoxicity of, in human T-lymphoblast leukemia cells, by leucovorin, 381
Fludarabine, therapeutic profile of the human glioma line D-54 MG, in athymic mice, 849
Fludarabine phosphate
evaluation of, in renal cell carcinoma: a Southwest Oncology Group study, 543
phase II study of, in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group study, 1319
phase II study of, in previously untreated patients with hepatoma: a Southwest Oncology Group study, 1111
phase II trial of, in patients with head and neck cancer: a Southwest Oncology Group study, 1313
Fluoropyrimidine chemotherapy, thymidylate synthase gene amplification in a colon tumor resistant to, 261
5-Fluorouracil
bolus, combined with continuous-infusion cisplatin, in colorectal carcinoma, 975
cardiotoxicity of, 733
combined with cyclophosphamide and doxorubicin (CAF), multiple drug intensification after induction with, in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial, 1271
combined with cyclophosphamide, vincristine, and methotrexate (COMF), in the treatment of adenocarcinoma of unknown primary origin, 605
combined with cytarabine—ineffective treatment in advanced colorectal carcinoma: a Southeastern Cancer Study Group trial, 779
combined with doxorubicin and cisplatin (FAP), phase II trial of, in advanced gastric carcinoma, 1301
combined with doxorubicin and mitomycin (FAM) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
combined with floxuridine, enhancement of cytotoxicity of, in human T-lymphoblast leukemia cells, by leucovorin, 381
combined with folinic acid, an overview of the current status and future direction of clinical trials with, 1249
combined with high- and low-dose leucovorin as treatment for colorectal carcinoma, severe and fatal toxic effects observed from, 1122
combined with ifosfamide for treatment of adenocarcinoma of the pancreas, 1115
combined with methotrexate and alkylating agents, compared to 10-ethyl-10-deaza-aminopterin, against advanced metastatic disease in murine tumor models, 727
combined with simultaneous cisplatin as second-line treatment of head and neck cancer, 485
interactions of methotrexate and cyclophosphamide with the pharmacokinetics of, in an animal model, 1267
prolonged continuous-infusion, combined with weekly cisplatin in advanced colorectal cancer, pilot trial of, 615
weekly, combined with PALA: toxic and therapeutic effects in colorectal cancer, 253
Fluosol-DA, combined with carbogen breathing, survey of the effect of adding, to treatment with various chemotherapeutic agents, 173
Fluoxymesterone, combined with tamoxifen, response to, in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen, 685
Flurbiprofen, alone or combined with mopidamole, inhibitory action of, on tumor lung metastases formation in mice, 1089
Folinic acid, combined with 5-fluorouracil, an overview of the current status and future direction of clinical trials with, 1249
Food aversions, learned, management of, in cancer patients receiving chemotherapy, 1071

G

Gallium nitrate
combined with mitoguazone and etoposide, salvage chemotherapy of advanced lymphoma with, 47
in prostatic cancer: evaluation of antitumor activity and effects on bone turnover, 887
Gastric cancer *see* Cancer, gastric
Gastrointestinal tract cancer *see* Cancer, gastrointestinal tract
Germ cell cancer *see* Cancer, testicular
Gestrinone, oral: a novel antiprogestin with no antitumor activity in endocrine-sensitive breast cancer, 1091
Glioma *see* Cancer, central nervous system
Gonadal and sexual function, in male patients with hairy cell leukemia: lack of adverse effects of recombinant α2b-interferon treatment, 179

H

Head and neck cancer see Cancer, head and neck
Hepatocellular cancer *see* Cancer, hepatocellular
Hepatoma *see* Cancer, hepatoma
Hexamethylene bisacetamide-induced cutaneous vasculitis, 471
Hexamethylmelamine
combined with cisplatin and continuous infusion of etoposide, phase II trial of, in extensive-disease small cell carcinoma of the lung, 575
combined with melphalan, compared to melphalan alone, in patients with persistent disease after doxorubicin and cisplatin (second-line chemotherapy of stage III–IV ovarian carcinoma), 277
contribution of prednisone to the effectiveness of, in multiple myeloma, 807
role of, in the treatment of ovarian cancer: where is the needle in the haystack? 666
Hickman catheter
acute thyroiditis as a complication of chemotherapy administration through a, 788
clots from: a common occurrence despite daily heparin flushing, 651
High-performance liquid chromatographic assays, for taxol in human plasma and urine and pharmacokinetics in a phase I trial, 53

Hodgkin's disease *see* Cancer, Hodgkin's disease
Homoharringtonine, phase I trial of, in children with refractory leukemia, 1245
Hormonal therapy, combined with chemotherapy in the treatment of malignant melanoma, 465
Hydrochloric acid, multivesicular liposomes containing cytarabine entrapped in the presence of, for intracavitary chemotherapy, 705
Hydroxyurea, combined with carmustine and dacarbazine, as adjunctive chemotherapy in stage I malignant melanoma, lack of benefit of: a Southwest Oncology Group study, 643
Hyperthermia
effect of, on the sensitivity of human colon carcinoma cells to mitoxantrone, 831
intraluminal microwave, combined with chemotherapy, preliminary report on the treatment of esophageal cancer by, 1013
local, combined with temperature-sensitive liposomes containing bleomycin, selective treatment of metastatic lymph nodes with, 1053

I

Idarubicin
administered iv to pediatric patients with acute lymphoblastic leukemia, phase II study of, 855
given orally in the treatment of anthracycline-naive advanced breast cancer patients, phase II study of, 451
oral, as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients, 1279
oral, phase II study of, in extensive disease small cell lung carcinoma: testing new drugs may prejudice the results of standard treatment, 1227
oral, phase II study of, in patients with AIDS-associated Kaposi's sarcoma, 775
orally administered, phase II evaluation of, in patients with advanced breast cancer, 1289
phase II study of, in advanced endometrial carcinoma, 535
phase II trial of, in patients with pancreatic cancer, 657
in the treatment of relapsed or refractory acute myeloid leukemia, 991
Ifosfamide
combined with *N*-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group trial, 431
combined with etoposide and cisplatin in the treatment of advanced non-small cell lung cancer, 1311
combined with 5-fluorouracil for treatment of adenocarcinoma of the pancreas, 1115
combined with mesna, and hematuria, 1124
combined with mesna, phase II trial of, in advanced colorectal cancer, 663
combined with mesna, phase II trial of, in metastatic adult renal carcinoma, 1103
combined with mitomycin and cisplatin in advanced non-small cell lung cancer, 851
combined with teniposide, phase II evaluation of, in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group study, 713
-induced subclinical tubular nephrotoxicity despite mesna, 127
phase II trial of, in children with malignant solid tumors, 131
Immunotherapy
media for LAK cell generation, 104
synergy between low-dose chemotherapy and, in mouse L1210 leukemia, 241
In vitro studies *see also* Cell culture studies
acute myocardial effects of mitoxantrone in the rabbit, 529
selective enhancement by menadiol of in vitro drug activity in human lymphatic neoplasms, 619
semiautomated colorimetric assay for in vitro screening of anticancer compounds, 1141
Indicine *N*-oxide, clinical use of a pyrrolizidine alkaloid, 517
Infants *see also* Children, less than 1 year of age with acute lymphoblastic leukemia treated with intensive multiagent chemotherapy, improved survival of, 1033
Interferon
high-dose human lymphoblastoid, in metastatic colorectal cancer: clinical results and modification of biological responses, 39
high-dose lymphoblastoid, in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group study, 165
human leukocyte, treatment of malignant endocrine pancreatic tumors with, 31
rDNA alfa-2b, phase II trial of, in patients with malignant carcinoid tumor, 1265
recombinant alfa-2a, phase II study of, in patients with advanced bone sarcomas, 747
recombinant alfa-2b, gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of treatment with, 179
recombinant beta (IFN-β_{ser}), combined with recombinant interferon-gamma, phase I trial of, in patients with advanced malignancy, 945
recombinant beta (IFN-β_{ser}), open-label phase II trial of, in patients with colorectal cancer, 983
recombinant beta, phase II trial of, in advanced colorectal cancer, 965
recombinant gamma, combined with recombinant beta interferon, phase I trial of, in patients with advanced malignancy, 945
recombinant gamma, phase II study of, in patients with advanced nonosseous sarcomas, 211
recombinant gamma, phase II study of, in patients with disseminated malignant melanoma, 843
Interleukin-2, recombinant, synergistic effect of, on the inhibition of growth of adenocarcinoma 755 by mitomycin, 567
4-Ipomeanol, preclinical toxicology studies of: a novel candidate for clinical evaluation in lung cancer, 1157
Iproplatin
in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study, 1049
phase I study of, in pediatric patients: a Pediatric Oncology Group study, 87
phase II evaluation of, in refractory germ cell tumors: a Southeastern Cancer Study Group trial, 863
phase II study of, in metastatic breast carcinoma, 1193
in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University study, 723
Isotretinoin, phase II study of, in the treatment of advanced non-small cell lung cancer, 1097

K

Kaposi's sarcoma *see* Cancer, sarcoma
Kidney cancer *see* Cancer, renal

L

LAK cell generation, media for, 104
Learned food aversions, management of, in cancer patients

receiving chemotherapy, 1071
Leucovorin
enhancement by, of cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells, 381
high- and low-dose, combined with 5-fluorouracil in the treatment of colorectal carcinoma, severe and fatal toxic effects observed from, 1122
Leukemia
acute lymphoblastic, improved survival of infants less than 1 year of age with, treated with intensive multiagent chemotherapy, 1033
acute lymphoblastic, phase II study of idarubicin administered iv to pediatric patients with, 855
acute myelogenous, influence of daunorubicin and cytarabine sequencing on the outcome of therapy in: a randomized trial, 571
acute myeloid, continuous-infusion diaziquone in: a Southeastern Cancer Study Group trial, 309
acute myeloid, in first remission, high-dose busulfan and amsacrine with autologous bone marrow rescue in patients with, 552
acute myeloid, phase II study of mitoxantrone and cytarabine in, 161
acute nonlymphoblastic, etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of, in a protocol adjusted for age, 201
acute nonlymphocytic, azacitidine in: 10 years later, 737
acute nonlymphocytic, oral idarubicin as single-agent treatment of, in poor-risk patients, 1279
adult acute nonlymphocytic, prolonged unmaintained remission after intensive consolidation therapy, 137
cells, human, effect of amsacrine on ara-CTP cellular pharmacology in, during high-dose cytarabine therapy, 479
cells, human T-lymphoblast, enhancement of cytotoxicity of floxuridine and 5-fluorouracil in, by leucovorin, 381
hairy cell, gonadal and sexual function in male patients with: lack of adverse effects of recombinant α2b-interferon treatment, 179
refractory acute myelogenous, continuous-infusion amsacrine in patients with, 113
refractory adult acute lymphocytic, phase II evaluation of teniposide and ifosfamide in: a Southwest Oncology Group study, 713
refractory, phase I trial of homoharringtonine in children with, 1245
refractory, phase I trial of *N*-methylformamide in pediatric patients with, 1299
relapsed acute lymphoblastic, total-body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with, 645
relapsed and refractory acute nonlymphocytic, combination chemotherapy with diaziquone and amsacrine in: a Cancer and Leukemia Group B study, 879
relapsed or refractory acute myeloid, idarubicin in the treatment of, 991
relapsed/refractory acute nonlymphocytic, phase II study of continuous-infusion diaziquone in, 755
resistant acute myelogenous, phase II study of amsacrine and high-dose cytarabine for, 881
resistant or relapsed acute nonlymphoid, combination of 6-mercaptopurine, vincristine, methotrexate, and prednisone in, 751
Light exposure, experimental dacarbazine antitumor activity and skin toxicity in relation to, 267
Liposomes
multivesicular, containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy, 705
multivesicular, containing cytarabine for slow-release sc administration, 447
temperature-sensitive, containing bleomycin, combined with local hyperthermia, selective treatment of metastatic lymph nodes with, 1053
Liver metastases, from colorectal adenocarcinoma, oral urea in the treatment of, 1119
Lomustine
combined with etoposide and methotrexate, third-line chemotherapy for resistant Hodgkin's disease with, 475
combined with etoposide, vindesine, and dexamethasone (CEVD), in Hodgkin's lymphoma refractory to COPP and ABVD: a multicenter trial of the German Hodgkin Study Group, 1203
combined with teniposide, treatment of advanced refractory lymphoma with, 215
pulmonary toxicity of, 786
Lonidamine, phase II study of, in patients with small cell carcinoma of the lung, 1283
Lorazepam, combined with high-dose metoclopramide, compared to prochlorperazine and lorazepam, for the control of emesis in patients receiving cytotoxic chemotherapy, 1007
Lung cancer *see* Cancer, lung
Lymph nodes
metastatic, in rats, transnodal cancer chemotherapy for, 235
metastatic, selective treatment of, with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin, 1053
Lymphatic cancer *see* Cancer, lymphatic
Lymphoma *see* Cancer, lymphoma

M

Marker surge, following chemotherapy of testis tumors, 785
Mastectomy, radical, without radiotherapy, compared to simple, with radiotherapy, in breast cancer: overview of randomized trials, 7
Medical costs, in treatment research, 107
Medroxyprogesterone acetate
combined with tamoxifen, treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with, 327
high-dose, oral versus im administration of, in pretreated patients with advanced breast cancer, 1151
oral, phase II evaluation of, in advanced breast cancer: a Northern California Oncology Group study, 969
variation in serum concentrations achieved with three commercially available preparations of, 813
Megestrol acetate, compared to the antiprogestin mifepristone (RU 486), the LHRH-analog buserelin, and ovariectomy in the treatment of rat mammary tumors, 1021
Melanoma *see* Cancer, melanoma
Melphalan
combined with cyclophosphamide, cisplatin, and carmustine: high-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience, 119
combined with hexamethylmelamine, compared to melphalan alone, in patients with persistent disease after doxorubicin and cisplatin (second-line chemotherapy of stage

III–IV ovarian carcinoma), 277
iv, in children, 1277
therapeutic profile of the human glioma line D-54 MG in athymic mice, 849
Menadiol, selective enhancement by, of in vitro drug activity in human lymphatic neoplasms, 619
Meningioma, preceding breast cancer, 550
Menogaril
administered as a 72-hour continuous iv infusion, phase I and pharmacokinetic study of, 593
iv, phase II study of, in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study, 771
and mitoxantrone, cross-resistance of, in a subline of P388 leukemia resistant to doxorubicin, 195
phase II trial of, in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial, 871
6-Mercaptopurine, combined with vincristine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia, 751
Mesna
combined with ifosfamide, and hematuria, 1124
combined with ifosfamide in a phase II trial in advanced colorectal cancer, 663
combined with ifosfamide in a phase II trial in metastatic adult renal carcinoma, 1103
ifosfamide-induced subclinical tubular nephrotoxicity despite, 127
Mesothelioma *see* Cancer, mesothelioma
Methotrexate
combined with cyclophosphamide, vincristine, and 5-fluorouracil (COMF), in the treatment of adenocarcinoma of unknown primary origin, 605
combined with doxorubicin, in adult soft tissue sarcoma, 1087
combined with 5-fluorouracil and alkylating agents, compared to 10-ethyl-10-deaza-aminopterin, against advanced metastatic disease in murine tumor models, 727
combined with lomustine and etoposide, third-line chemotherapy for resistant Hodgkin's disease with, 475
combined with 6-mercaptopurine, vincristine, and prednisone in resistant or relapsed acute nonlymphoid leukemia, 751
combined with teniposide, demonstration of a schedule-dependent therapeutic synergism utilizing, in L1210 leukemia, 581
and cyclophosphamide, interactions of, with the pharmacokinetics of 5-fluorouracil in an animal model, 1267
oral, combined with dipyridamole, phase II trial of, in colorectal carcinoma, 821
Methylene dimethane sulfonate, phase I clinical trial of, 817
***N*-Methylformamide**
oral, phase II study on, in metastatic colorectal cancer, 1293
phase I trial of, in pediatric patients with refractory leukemias, 1299
phase II study of, in patients with advanced colorectal cancer, 541
Methylphenidate, associated with narcotics for the treatment of cancer pain, 67
Metoclopramide
continuous high-dose, efficacy of, in patients receiving daily cisplatin infusions, 979
continuous subcutaneous infusion of, for treatment of narcotic bowel syndrome, 1121
high-dose, combined with lorazepam, compared to prochlorperazine and lorazepam, for the control of emesis in patients receiving cytotoxic chemotherapy, 1007
pharmacokinetic comparison of intranasal, oral, and intramuscular administration of, in healthy volunteers, 317
Mifepristone (RU 486), compared to the progestin megestrol acetate, the LHRH-analog buserelin, and ovariectomy in the treatment of rat mammary tumors, 1021
Mitoguazone
combined with eflornithine in the treatment of recurrent primary brain tumors, phase I–II study of, 459
combined with gallium nitrate and etoposide, salvage chemotherapy of advanced lymphoma with, 47
phase II evaluation of, in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial, 89
Mitomycin
combined with etoposide, sudden dyspnea occurring 24 hours after, 103
combined with 5-fluorouracil and doxorubicin (FAM) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
combined with ifosfamide and cisplatin in advanced non-small cell lung cancer, 851
combined with mitoxantrone in previously treated patients with advanced breast cancer, 191
combined with vindesine and cisplatin in the treatment of head and neck squamous cell carcinoma, 81
combined with vindesine and mitoxantrone (VMMc), long duration of response with, in metastatic breast cancer: a pilot phase II study, 845
effects of the mode of administration of, on tumor and marrow response and on the therapeutic ratio, 927
phase II trial of, in malignant mesothelioma, 857
synergistic effect of recombinant interleukin-2 on the inhibition of growth of adenocarcinoma 755 by, 567
Mitoxantrone
acute myocardial effects of, in the rabbit, 529
for carcinoma of the endometrium: a phase II trial of the Gynecologic Oncology Group, 217
cardiotoxicity in patients treated with: Southwest Oncology Group phase II studies, 609
combined with cytarabine, phase II study of, in acute myeloid leukemia, 161
combined with doxorubicin, phase II trial of, in metastatic breast cancer, 921
combined with etoposide, cisplatin, and prednisolone, salvage chemotherapy for non-Hodgkin's lymphoma with, 639
combined with mitomycin in previously treated patients with advanced breast cancer, 191
combined with vindesine and mitomycin (VMMc), long duration of response with, in metastatic breast cancer: a pilot phase II study, 845
compared to doxorubicin, for effects on energy metabolism of the rat heart, 361
effect of hyperthermia on the sensitivity of human colon carcinoma cells to, 831
injury from extravasation of, 992
and menogaril, cross-resistance of, in a subline of P388 leukemia resistant to doxorubicin, 195
phase II study of, in epithelial ovarian cancer, 627
phase II study of, in untreated and previously minimally treated patients with metastatic soft tissue sarcomas, 1109
phase II trial of, as first-line chemotherapy for extensive small cell lung cancer, 1291
in the treatment of patients with non-Hodgkin's lymphoma,

1209
Mopidamole, alone or combined with flurbiprofen, inhibitory action of, on tumor lung metastases formation in mice, 1089
Multiple drug intensification, after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial, 1271
Myeloma *see* Cancer, myeloma

N

Narcotics
continuous sc infusion of, for the treatment of cancer pain: an update, 953
continuous sc infusion of metoclopramide for treatment of narcotic bowel syndrome, 1121
continuous sc infusion of, using a portable disposable device in patients with advanced cancer, 635
methylphenidate associated with, for the treatment of cancer pain, 67
trans-$N_3P_3Az_2(NHMe)_4$, phase I and pharmacokinetic study of, 155

O

Ovarian cancer *see* Cancer, ovarian
Ovariectomy, compared to the antiprogestin mifepristone (RU 486), the progestin megestrol acetate, and the LHRH-analog buserelin in the treatment of rat mammary tumors, 1021

P

PAC (cisplatin, doxorubicin, and cyclophosphamide), in the treatment of mixed mesodermal tumor of the ovary, 1275
Pain
from cancer, continuous sc infusion of narcotics for the treatment of: an update, 953
from cancer, methylphenidate associated with narcotics for the treatment of, 67
continuous sc infusion of narcotics using a portable disposable device in patients with advanced cancer, 635
PALA, weekly 5-fluorouracil combined with: toxic and therapeutic effects in colorectal cancer, 253
Pancreatic cancer *see* Cancer, pancreatic
Paying for patient care in treatment research—who is responsible? 107
PCNU
phase II study of, in advanced renal cell carcinoma, 331
therapeutic profile of the human glioma line D-54 MG in athymic mice, 849
Peplomycin, phase II study of, in advanced breast carcinoma, 777
Pharmacokinetics
action of 7-ethylcamptothecin on tumor cells and its disposition in mice, 341
of carboplatin after iv administration, 1231
chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity, 283
comparison of intranasal, oral, and intramuscular metoclopramide in healthy volunteers, 317
of continuous-infusion high-dose thiotepa, 1043
distribution of clomesone in mice, 1135
doxorubicin distribution in human breast cancer, 1221
effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy, 479
of 5-fluorouracil in an animal model, interactions of methotrexate and cyclophosphamide with, 1267
of high-dose teniposide, 599
and immediate effects of high-dose carmustine in man, 433
medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations, 813
multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy, 705
phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous iv infusion, 593
phase I and pharmacokinetic study of *trans*-$N_3P_3Az_2(NHMe)_4$, 155
phase I trial of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation, 141
scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration, 717
of taxol in a phase I trial, using high-performance liquid chromatographic assay for taxol in human plasma and urine, 53
of vinblastine, limited sampling model for, 935
Phase I studies
of caracemide using bolus and infusion schedules, 349
of combinations of recombinant interferons β_{ser} and γ in patients with advanced malignancy, 945
of echinomycin, 1217
of epirubicin given on a weekly schedule, 273
of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy, 101
of homoharringtonine in children with refractory leukemia, 1245
of iproplatin in pediatric patients: a Pediatric Oncology Group study, 87
of menogaril administered as a 72-hour continuous iv infusion, 593
of methylene dimethane sulfonate, 817
of *N*-methylformamide in pediatric patients with refractory leukemias, 1299
of *trans*-$N_3P_3Az_2(NHMe)_4$, 155
pediatric, of carboplatin: a Children's Cancer Study Group report, 1039
of procarbazine as a 5-day continuous infusion in children with central nervous system tumors, 973
of taxol, administered as a short iv infusion daily for 5 days, 1179
of taxol, in patients with advanced cancer, 1171
of taxol, pharmacokinetics in, using high-performance liquid chromatographic assay for taxol in human plasma and urine, 53
of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation, 141
of two schedules of teroxirone, 489
Phase II studies
of acivicin in malignant mesothelioma, 545
of aclarubicin in non-small cell lung cancer, 323
of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group trial, 773
of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Can-

cer Council trial, 649
of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia, 881
of anaxirone in advanced non-small cell lung cancer, 539
of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group study, 1101
of caracemide in advanced or recurrent non-small cell lung cancer, 1099
of carboplatin in advanced malignant melanoma, 171
of carboplatin in advanced, refractory germ cell neoplasms: an Eastern Cooperative Oncology Group study, 989
of carboplatin in patients with advanced germ cell tumors refractory to cisplatin, 197
of carboplatin in previously untreated patients with metastatic small cell lung carcinoma, 311
of carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study, 1049
of carmustine in advanced upper aerodigestive cancer, 781
of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract, 329
of cisplatin and etoposide in children with advanced soft tissue sarcoma: a report from the Italian Cooperative Rhabdomyosarcoma Group, 525
of the combination of carmustine and 6-thioguanine in advanced malignant melanoma, 429
of a combination of doxorubicin and mitoxantrone in metastatic breast cancer, 921
of the combination of vinblastine plus cisplatin administered by continuous 120-hour infusion for patients with advanced malignant melanoma, 769
of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma, 1301
of continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial, 309
of continuous-infusion diaziquone in relapsed/refractory acute nonlymphocytic leukemia, 755
of continuous infusion of etoposide, cisplatin, and hexamethylmelamine in extensive-disease small cell carcinoma of the lung, 575
of cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma, 187
of dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma, 997
of 10-deaza-aminopterin in advanced breast cancer, 95
of deoxydoxorubicin in patients with advanced liver cancer, 1117
of 4′-deoxydoxorubicin in advanced non-small cell lung cancer, 861
of diaziquone in pancreatic carcinoma: a Southwest Oncology Group study, 1309
of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group study, 1095
of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study, 1295
of 5,6-dihydro-5-azacitidine in extensive, untreated non-small cell lung cancer, 859
of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council trial, 765
of esorubicin in patients with advanced melanoma, 325
of esorubicin in patients with advanced non-small cell lung cancer, 783
of esorubicin in the treatment of metastatic carcinoma of the kidney: a study of the Northern California Oncology Group, 767
of etoposide in APUD tumors, 305
of etoposide in previously untreated squamous cell carcinoma of the head and neck, 321
of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study, 1303
of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study, 661
of etoposide in the management of advanced or recurrent squamous cell carcinoma of the vulva and carcinoma of the vagina: a Gynecologic Oncology Group study, 869
of FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group study, 1313
of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group study, 1319
of fludarabine phosphate in previously untreated patients with hepatoma: a Southwest Oncology Group study, 1111
of high-dose cytarabine and cisplatin in locoregional previously untreated squamous carcinoma of the head and neck: a Piedmont Oncology Association study, 151
of high-dose etoposide and autologous bone marrow transplantation in central nervous system gliomas, 759
how large should a phase II trial of a new drug be? 1079
of idarubicin administered iv to pediatric patients with acute lymphoblastic leukemia, 855
of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients, 451
of idarubicin in advanced endometrial carcinoma, 535
of idarubicin in patients with pancreatic cancer, 657
identification of new drugs in small cell lung cancer: phase II agents first? 1131
of ifosfamide and mesna in advanced colorectal cancer, 663
of ifosfamide in children with malignant solid tumors, 131
of ifosfamide/mesna in metastatic adult renal carcinoma, 1103
of iproplatin in metastatic breast carcinoma, 1193
of iproplatin in refractory germ cell tumors: a Southeastern Cancer Study Group trial, 863
of isotretinoin in the treatment of advanced non-small cell lung cancer, 1097
of iv menogaril in patients with malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study, 771
of lonidamine in patients with small cell carcinoma of the lung, 1283
of low-dose weekly epirubicin in metastatic prostate cancer: a European Organization for Research and Treatment of Cancer (EORTC) study, 1317
of menogaril in patients with advanced colorectal carcinoma: an Illinois Cancer Council trial, 871
of *N*-methylformamide in patients with advanced colorectal cancer, 541
of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial, 89
of mitomycin in malignant mesothelioma, 857
of mitoxantrone and cytarabine in acute myeloid leukemia, 161
of mitoxantrone as first-line chemotherapy for extensive

small cell lung cancer, 1291
of mitoxantrone, cardiotoxicity in patients in: Southwest Oncology Group, 609
of mitoxantrone for carcinoma of the endometrium: a study by the Gynecologic Oncology Group, 217
of mitoxantrone in epithelial ovarian cancer, 627
of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas, 1109
of multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group trial, 1271
1970–1985, clinical drug development: an analysis of, 71
open-label, of recombinant beta interferon (IFN-β_{ser}) in patients with colorectal cancer, 983
of oral idarubicin in extensive disease small cell lung carcinoma: testing new drugs may prejudice the results of standard treatment, 1227
of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma, 775
of oral medroxyprogesterone acetate in advanced breast cancer: a Northern California Oncology Group study, 969
of oral methotrexate and dipyridamole in colorectal carcinoma, 821
of oral *N*-methylformamide in metastatic colorectal cancer, 1293
of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer, 763
of orally administered idarubicin in patients with advanced breast cancer, 1289
of PCNU and bisantrene in advanced renal cell carcinoma, 331
of peplomycin in advanced breast carcinoma, 777
of prednimustine as first-line chemotherapy in patients with advanced breast cancer, 1107
of prednimustine in advanced malignant melanoma, 1315
of rDNA alfa-2b interferon in patients with malignant carcinoid tumor, 1265
of recombinant alfa-2a interferon in patients with advanced bone sarcomas, 747
of recombinant beta interferon in advanced colorectal cancer, 965
of recombinant gamma-interferon in patients with advanced nonosseous sarcomas, 211
of recombinant interferon-gamma in patients with disseminated malignant melanoma, 843
of the single agents Baker's antifol, diaziquone, and epirubicin in advanced pancreatic cancer, 865
of spirogermanium in advanced adenocarcinoma of the prostate: a Southwest Oncology Group study, 1305
of spirogermanium in central nervous system tumors: a Southwest Oncology Group study, 99
of spirogermanium in malignant melanoma: a Southwest Oncology Group study, 985
of spirohydantoin mustard for the treatment of recurrent malignant gliomas, 1105
of streptozocin in the treatment of advanced renal cell carcinoma, 97
of tauromustine as second-line chemotherapy in metastatic breast cancer in postmenopausal women, 987
of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group study, 713
of teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group study, 1307
of teniposide in squamous cell carcinoma of the cervix: a trial of the Gynecologic Oncology Group, 873
of tiazofurin in colorectal cancer: a National Cancer Institute of Canada study, 1297
of tiazofurin in recurrent squamous cell carcinoma of the head and neck, 425
of tricyclic nucleoside phosphate for advanced colorectal cancer, 333
of 1,2,4-triglycidylurazol in advanced breast cancer: a trial of the Phase II Study Group of the Association of Medical Oncology, German Cancer Society, 93
of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma, 209
of vinblastine and bleomycin in advanced ovarian cancer, 335
of vindesine in malignant pleural mesothelioma, 205
of vindesine-mitoxantrone-mitomycin (VMMc) combination chemotherapy in metastatic breast cancer: a pilot study, 845
Phase I–II study, of eflornithine and mitoguazone combined in the treatment of recurrent primary brain tumors, 459
Piritrexim (BW301U), oral, phase II trial of, in patients with stage III non-small cell lung cancer, 763
Plasma perfusion, over immobilized staphylococcal Protein A, clinical trial of, in metastatic breast cancer, 411
Platinum analogs, in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University study, 723
Prednimustine
in advanced malignant melanoma: a phase II study, 1315
phase II trial of, as first-line chemotherapy in patients with advanced breast cancer, 1107
Prednisolone, combined with mitoxantrone, etoposide, and cisplatin, as salvage chemotherapy for non-Hodgkin's lymphoma, 639
Prednisone
alternate-day, combined with weekly cyclophosphamide: an effective secondary therapy in multiple myeloma, 981
combined with cyclophosphamide, vincristine, and procarbazine (COPP); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
combined with 6-mercaptopurine, vincristine, and methotrexate in resistant or relapsed acute nonlymphoid leukemia, 751
contribution of, to the effectiveness of hexamethylmelamine in multiple myeloma, 807
Procarbazine
combined with cyclophosphamide, vincristine, and prednisone (COPP); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
as a 5-day continuous infusion in children with central nervous system tumors, phase I trial of, 973
Prochlorperazine, combined with lorazepam, compared to high-dose metoclopramide and lorazepam, for the control of emesis in patients receiving cytotoxic chemotherapy, 1007
Prognostic marker, cell kinetics as, in locally advanced breast cancer, 375
Prostatic cancer *see* Cancer, prostatic
Protein kinase C inhibitors, putative, perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of, 1239
Pyran copolymer, increased therapeutic efficacy and reduced toxicity of doxorubicin linked to, via the side chain of the

drug, 367

R

Radiotherapy
acute laryngeal edema after single-dose irradiation and doxorubicin, 1322
with concurrent cisplatin and etoposide in locally advanced non-small cell lung cancer, 681
overview of randomized trials comparing radical mastectomy without, against simple mastectomy with, in breast cancer, 7
pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M_0 non-small cell lung cancer, 895
postoperative adjuvant, in breast cancer, overview of randomized trials of, 15
therapeutic profile of the human glioma line D-54 MG in athymic mice, 849
total-body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia, 645
Renal cancer *see* Cancer, renal
Renal cell cancer *see* Cancer, renal cell
Research reviews, of randomized clinical trials, 3
Retinoids, as preventive and therapeutic anticancer agents, 391, 493

S

Sarcoma *see* Cancer, sarcoma
Scalp cooling, effectiveness of, in reducing alopecia caused by epirubicin treatment of advanced breast cancer, 913
Sedation, severe, and delirium in patients with terminal cancer, 787
Semiautomated colorimetric assay, for in vitro screening of anticancer compounds, 1141
Solid tumors *see* Cancer, solid tumors
Spirogermanium
phase II evaluation of, in malignant melanoma: a Southwest Oncology Group study, 985
phase II study of, in advanced adenocarcinoma of the prostate: a Southwest Oncology Group study, 1305
phase II trial of, in central nervous system tumors: a Southwest Oncology Group study, 99
therapy for advanced renal cell cancer with: a Southwest Oncology Group study, 207
Spirohydantoin mustard, phase II study of, for the treatment of recurrent malignant gliomas, 1105
Staphylococcal Protein A, immobilized, clinical trial of plasma perfusion over, in metastatic breast cancer, 411
Streptozocin, phase II trial of, in the treatment of advanced renal cell carcinoma, 97
Surface area, actual versus ideal weight in the calculation of: effects on dose of 11 chemotherapy agents, 907

T

Tamoxifen
adjuvant, response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of, 685
combined with decarbazine, cisplatin, and carmustine in the treatment of malignant melanoma, 465
combined with doxorubicin, compared to doxorubicin alone, controlled clinical trial of, in hepatocellular carcinoma, 1213
combined with fluoxymesterone, response to, in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen, 685
combined with medroxyprogesterone acetate, treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with, 327
therapy with, in unresectable adenocarcinoma of the pancreas, 749
Tauromustine, second-line chemotherapy with, in metastatic breast cancer in postmenopausal women: a phase II study, 987
Taxol
high-performance liquid chromatographic assay for, in human plasma and urine and pharmacokinetics in a phase I trial, 53
phase I study of, administered as a short iv infusion, daily for 5 days, 1179
phase I trial of, in patients with advanced cancer, 1171
TCNU, hematopoietic effects of, in mice, 837
Teniposide
combined with cytarabine and cisplatin in the treatment of refractory non-Hodgkin's lymphomas of unfavorable histology, 659
combined with ifosfamide, phase II evaluation of, in refractory adult acute lymphocytic leukemia: a Southwest Oncology Group study, 713
combined with lomustine, treatment of advanced refractory lymphoma with, 215
combined with methotrexate, demonstration of a schedule-dependent therapeutic synergism utilizing, in L1210 leukemia, 581
high-dose, combined with total-body irradiation, preceding bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia: a pilot study, 645
high-dose, pharmacokinetics of, 599
phase II study of, in metastatic renal and bladder cancer: a Southwest Oncology Group study, 1307
in squamous cell carcinoma of the cervix: a phase II trial of the Gynecologic Oncology Group, 873
in the treatment of non-small cell lung carcinoma, 83
Teroxirone, phase I study of two schedules of, 489
Testicular cancer *see* Cancer, testicular
6-Thioguanine
combined with carmustine, phase II study of, in advanced malignant melanoma, 429
combined with daunorubicin and cytarabine in acute myelogenous leukemia: effect of daunorubicin and cytarabine sequencing on the outcome of therapy, 571
combined with etoposide, cytarabine, and doxorubicin for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age, 201
Thiotepa
continuous-infusion high-dose, pharmacokinetics of, 1043
high-dose iv, combined with cryopreserved autologous bone marrow transplantation for therapy of refractory cancer, 689
Thoracotomy, in initially inoperable stage III M_0 non-small cell lung cancer, pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to, 895
Thymidylate synthase gene amplification, in a colon tumor

resistant to fluoropyrimidine chemotherapy, 261
Thyroid cancer *see* Cancer, thyroid
Tiazofurin
administered by iv bolus daily for 5 days, phase I trial of, with pharmacokinetic evaluation, 141
phase II study of, in colorectal cancer: a National Cancer Institute of Canada study, 1297
phase II trial of, in recurrent squamous cell carcinoma of the head and neck, 425
Timing, may be a critical factor in drug therapy, 1321
Transient tumor marker surge, following chemotherapy of testis tumors, 785
Transnodal cancer chemotherapy, for metastatic lymph nodes in rats, 235
Triazinate, combined with FAM (5-fluorouracil,, doxorubicin, and mitomycin) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization, 419
Tricyclic nucleoside 5′-phosphate, phase II clinical trial of, for advanced colorectal cancer, 333
1,2,4-Triglycidylurazol
in advanced breast cancer: a trial of the Phase II Study Group of the Association of Medical Oncology, German Cancer Society, 93
phase II trial of, in patients with metastasized renal cell carcinoma, 209
Trilostane, a new hormonal agent in advanced postmenopausal breast cancer, multicenter study of, 1197
Tumor systems, animal *see also* Xenografts
action of 7-ethylcamptothecin on tumor cells and its disposition in mice, 341
adenocarcinoma 755, synergistic effect of recombinant interleukin-2 on the inhibition of growth of, by mitomycin, 567
combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models, 727
comparison of the actions of the antiprogestin mifepristone (RU 486), the progestin megestrol acetate, the LHRH-analog buserelin, and ovariectomy in the treatment of rat mammary tumors, 1021
effects of intralesional versus ip administration of cisplatin on squamous cell carcinoma of mice, 825
effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio, 927
evaluation of antitumor activity of 1-β-D-arabinofuranosyl-2-amino-1,4(2*H*)-4-iminopyrimidine in murine tumors, 441
experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes, 267
inhibitory action of flurbiprofen and mopidamole on tumor lung metastases formation in mice, 1089
interaction of etoposide and cisplatin in an in vitro tumor model, 673
interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model, 1267
mouse L1210 leukemia demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in, 581
multivesicular liposomes containing cytarabine entrapped in the presence of hydrochloric acid for intracavitary chemotherapy, 705
multivesicular liposomes containing cytarabine for slow-release sc administration, 447
P388 leukemia, cross-resistance of menogaril and mitoxantrone in a doxorubicin-resistant subline of, 195
potentiation of cytotoxicity of zinostatin under acidic conditions in vitro and in vivo, 247
selective treatment of metastatic lymph nodes with combination of local hyperthermia and temperature-sensitive liposomes containing bleomycin, 1053
survey of the effect of adding Fluosol-DA 20%/O_2 to treatment with various chemotherapeutic agents, 173
synergy between low-dose chemotherapy and immunotherapy in, 241
transnodal cancer chemotherapy for metastatic lymph nodes in rats, 235

U

Urea, oral, in the treatment of liver metastases from colorectal adenocarcinoma, 1119
Uterine cancer *see* Cancer, uterine

V

Vaginal cancer see Cancer, vaginal
Verapamil, reversal of vincristine resistance by, and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells, 353
Vinblastine
combined with bleomycin, phase II study of, in advanced ovarian cancer, 335
combined with cisplatin administered by continuous 120-hour infusion, phase II study of, for patients with advanced malignant melanoma, 769
combined with doxorubicin, bleomycin, and dacarbazine (ABVD); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
continuous 5-day infusion of, for percutaneous hepatic arterial chemotherapy of metastatic breast cancer, 1001
continuous-infusion, for treatment of refractory adenocarcinoma of the cervix, 547
limited sampling model for pharmacokinetics of, 935
Vincristine
combined with cyclophosphamide and doxorubicin, addition of etoposide to, for remission induction and survival in patients with small cell lung cancer, 61
combined with cyclophosphamide and doxorubicin in etoposide and cisplatin-resistant small cell lung cancer, 941
combined with cyclophosphamide, methotrexate, and 5-fluorouracil (COMF), in the treatment of adenocarcinoma of unknown primary origin, 605
combined with cyclophosphamide, procarbazine, and prednisone (COPP); lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to: a multicenter trial of the German Hodgkin Study Group, 1203
combined with dactinomycin: unexpected toxicity encountered in the National Wilms' Tumor Study, 993
combined with 6-mercaptopurine, methotrexate, and prednisone in resistant or relapsed acute nonlymphoid leukemia, 751
reappraisal of some dosage adjustment guidelines, 229
resistance, verapamil reversal of, and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells, 353

scheduling of: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration, 717
Vindesine
combined with dacarbazine and cisplatin in advanced malignant melanoma: a phase II study, 997
combined with lomustine, etoposide, and dexamethasone (CEVD), in Hodgkin's lymphoma refractory to COPP and ABVD: a multicenter trial of the German Hodgkin Study Group, 1203
combined with mitomycin and cisplatin, in the treatment of head and neck squamous cell carcinoma, 81
combined with mitoxantrone and mitomycin (VMMc), long duration of response with, in metastatic breast cancer: a pilot phase II study, 845
phase II trial of, in malignant pleural mesothelioma, 205
VMMc (vindesine-mitoxantrone-mitomycin), long duration of response with, in metastatic breast cancer: a pilot phase II study, 845
Vulval cancer *see* Cancer, vulval

W

Weight, actual versus ideal, in the calculation of surface area: effects on dose of 11 chemotherapy agents, 907

X

Xenografts
of childhood rhabdomyosarcoma, drug accumulation and response of, determined by frequency of administration of vincristine, 717
therapeutic profile of the human glioma line D-54 MG in athymic mice, 849
use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts, 297

Z

Zinostatin, potentiation of cytotoxicity of, under acidic conditions in vitro and in vivo, 247

Author Index

A

Abrams J, 541, 861
Abramson I, 297
Ackland S, 1007
Adams M, 349, 415
Adelstein P, 571
Ahlgren JD, 419, 788
Ahmann DL, 769, 843
Aisner J, 291, 861, 1099, 1131
Al-Sarraf M, 723
Alberti DB, 1179
Alberts DS, 267
Alcock N, 887
Alfano G, 751
Alm G, 31
Ames MM, 489
Andersen J, 119
Anderson AJ, 651
Anderson K, 119
Anderson NR, 201
Angel C, 1303
Anhalt GJ, 471
Antman K, 119, 1043
Aoki K, 247
Appelbaum FR, 101, 115
Applebaum EL, 321
Archimbaud E, 571
Ardizzoni A, 1311
Arkin CF, 201
Arnold C, 1071
Arnold H, 539
Arthur K, 749
Atkins C, 47
Atkins JN, 151
Atkinson EN, 327
Azouri N, 979

B

Baba T, 247
Bacha DM, 1245
Bachmann E, 361
Baer L, 549
Bagatella M, 83
Bagnulo S, 855
Baikadi M, 681
Bajorin D, 857
Bakemeier R, 215
Baker LH, 1095, 1217
Bakker GH, 1021
Balcerzak SP, 99, 643, 985
Balducci L, 543
Balslev I, 987
Band P, 1283
Baracco F, 1311
Baram T, 973
Barley V, 1197
Barni S, 665
Barón MG, 851
Barrelet L, 81
Barrett D, 1157
Barrett J, 871
Bartolucci AA, 773, 779
Barzan L, 257
Bast R, 119
Bastholt L, 451
Baum ES, 1039
Baum M, 15
Bavier AR, 559
Beckner SK, 104
Beecham J, 869, 1295
Beex L, 1151
Begg CB, 137, 1043
Beijnen JH, 992
Belani CP, 1099
Belasco JB, 1277
Belch A, 981
Bellet RE, 465
Belliveau JF, 975
Belpomme D, 845
Beltran G, 1111
Ben-Efraim S, 241
Benfield GFA, 1227
Bennett JM, 137
Benson AB, III, 871
Benz C, 283
Beougher K, 965
Berd D, 465
Berdel WE, 93
Berenberg J, 1307
Berger FG, 261
Berger MS, 459
Berger SH, 261
Bergsagel D, 981
Berkowitz LD, 763
Berman M, 1303
Bern MM, 201
Bernasconi S, 81
Bertino JR, 381, 1029
Betensky R, 907
Bigner DD, 849
Billingham ME, 427, 767
Birch R, 89, 431, 863
Bishop JF, 191, 273, 1007
Bitran JD, 311
Bizzini B, 241
Blackledge G, 627, 1197
Blessing JA, 661, 869, 1295, 1303
Bleyer WA, 1033
Blough R, 649, 765, 871
Blum R, 877
Blume KG, 645
Blumenstein BA, 543, 1305, 1307
Blumer JL, 689

Bobrow S, 1029
Boetius G, 1151
Bonadonna G, 375
Bonardi G, 83
Bonnett JD, 1095, 1309
Bono AV, 1317
Boraas M, 1071
Borden EC, 165, 545, 945
Bosl GJ, 197
Boutin C, 205
Boyd MR, 1157
Boyer MW, 651
Brada M, 655
Brambilla C, 205
Bramwell V, 1109
Brandes L, 981
Breed W, 1151
Bremer K, 93, 209
Brenneis C, 67, 635, 953, 1121
Brewer F, 353
Brito-Babapulle F, 161
Brodie G, 273
Brodovsky HS, 875, 989
Brown LB, 277
Brown TD, 965, 1101
Bruckner HW, 666
Bruera E, 67, 635, 787, 953, 1121
Brundrett RB, 53
Brunetti I, 485
Buckner CD, 101
Buckner J, 329
Budman D, 95
Bukowski RM, 543, 1307
Bundy BN, 217, 873
Burghouts J, 1151
Burke MT, 763, 783
Burkhart PT, 137
Burns I, 191
Burns W, 273
Butler K, 91
Buzdar AU, 411, 777, 1193

C

Cabanillas F, 631
Cadman E, 1029
Calabresi P, 975
Calciati A, 83
Calculli G, 525
Camacho FJ, 253
Campbell ED, 581
Candiani E, 1221
Cangir A, 973
Canino R, 855
Canobbio L, 1221
Cantrell JE, Jr, 91, 615
Capaccio A, 1311
Capizzi RL, 151, 195
Carcassonne Y, 991
Carde P, 1301
Carignan JR, 165
Carli M, 525, 855
Carlson RW, 427, 767, 969
Carmichael JA, 277, 455
Carney DN, 697
Carpenter J, 1271
Carr DT, 859
Carrasco CH, 313, 1001
Carter WH, Jr, 581
Casper ES, 171, 1289
Cassileth PA, 137
Castiglia G, 485
Cates AE, 53
Catovsky D, 161
Cazap E, 419
Ceci A, 525
Chachoua A, 775
Chadwick S, 67, 635, 787
Chamberlain MC, 459
Champion JE, 87
Champlin RE, 881
Chan A, 749
Chan E, 887
Chandrasekaran B, 195
Chang MN, 211, 429, 843
Chapman D, 813
Chapman R, 1185
Charnsangavej C, 313, 1001
Charuvanki V, 1324
Chen T-L, 53
Cheng EW, 305, 657, 663
Chernicoff D, 871
Chesterman CN, 1279
Chetiyawardana AD, 627
Choucair AK, 459
Christopherson WA, 661
Chun HG, 737
Ciobanu N, 1324
Citron ML, 317
Ciuffreda L, 83
Clark GM, 609
Clark JL, 261
Clark PI, 417
Clarke J, 549
Clift RA, 101
Coates AS, 191, 273, 1087
Cobleigh MA, 321
Cohen MH, 651
Colella R, 855
Coleman CN, 475, 659
Coleman M, 1067
Collins C, 733
Collins JM, 229
Colomer R, 550
Coltman CA, Jr, 713, 723, 1309, 1319
Colvin M, 53
Comelli A, 855
Comoretto R, 257
Conley BA, 861
Coombes RC, 1091
Coonley CJ, 47
Cooper IA, 1007
Copeland L, 547
Corkery JC, 201
Costanzi JH, 643, 1305
Costanzi JJ, 985
Cour V, 845
Cowan JD, 1101
Craig JB, 151

Crawford ED, 207, 543, 1305, 1307
Creagan ET, 211, 429, 489, 769, 781, 843
Creech RH, 907
Cripps C, 1109, 1297
Crispino S, 665
Crivellari D, 325
Crowley J, 99, 1095
Crowther D, 817
Cudillo L, 751
Culham CA, 141
Cullen MH, 1227
Cummings FJ, 975
Cunningham D, 1091
Cunningham-Rundles S, 39
Curley T, 887
Currie VE, 95, 1289
Cuzick J, 7, 15
Cvitkovic E, 1301

D

D'Angio GJ, 993
D'Incalci M, 1221
D'Onofrio G, 751
Dabouis G, 205
Daidone MG, 375
Daiter S, 179
Dalmark M, 451, 1315
Danieu L, 47
Davidson HS, 179
Davies B, 737
Davis M, 543
Davis RB, 755, 879
Davis RL, 459
Davis TE, 165, 331
De Bernardi B, 525, 855
de Bruijn EA, 1267
De Forges A, 1103
de Jong FH, 1021
De Lena M, 790
De Pauw M, 1317
De Rosa M, 71
de Vries EGE, 155
de Vries LGE, 599
Decker D, 1217
Decker RW, 881
DeGraw JI, 727
DeGregorio M, 283
Delitala G, 665
Denning D, 220
Dershaw D, 887
Deutsch M, 311
Dhingra HM, 859
Diehl V, 1203
di Montezemolo LC, 525
Di Petro N, 855
Di Pietro N, 325
Di Roberto P, 669
Di Tullio MT, 525
Dill PA, 619
Dill PL, 1239
Dimery IW, 349, 425
Dimling J, 195
DiSaia PJ, 217, 661, 869
Dixon D, 643
Dixon RH, 61
Doesburg W, 1151
Donadio M, 83
Donehower RC, 53, 471, 1171
Doney KC, 101
Donhujsen-Ant R, 209
Doroshow JH, 427
Dorr RT, 267
Dougherty J, 663
Douglass EC, 131
Douglass HO, Jr, 1122
Drakes T, 283
Drasga RE, 863
Driedger A, 1119
Driessen O, 1267
Droz JP, 1103, 1301
Duarte TE, 619, 1239
Dufour P, 991
Dugery C, 875
Dunlap WH, 559
Durand RE, 673
Durr FE, 831
Durrant KD, 913

E

Eagan RT, 895
Earhart RH, 331
Eder JP, 119, 1043
Edmonson JH, 199, 211, 747, 781
Ehrlich CE, 217
Einhorn LH, 431, 863
Einspahr J, 267
Einzig AI, 39
Einzig J, 329
Eisenberger M, 541, 861, 1099
Eisenhauer EA, 771, 1109, 1297
Eisenstaedt RS, 779
Elferink F, 1231
El-hawari M, 1157
Elias A, 119, 1043
Ellerton J, 755
Elson DL, 429
Elson PJ, 165, 331, 989
Engstrom PF, 253
Ensley J, 723
Enterline JP, 409
Epelman S, 421
Eriksson B, 31
Ernst P, 987
Esparza L, 777
Estevez RA, 419
Estey EH, 1113
Etcubanas E, 131
Ettinger DS, 53, 103, 471, 1171
Ettinger LJ, 1039
Evans LM, 171
Evans R, 1033
Evans WK, 941

F

Fabian CJ, 643
Fabiano F, 1311

Fahey JL, 187
Falchuk SC, 788
Falkson G, 545, 907
Falkson HC, 907
Farber L, 1029
Farbstein MJ, 187
Farhangi M, 1123
Feld R, 941
Felder TB, 1165
Feldman AR, 559
Felletti R, 1311
Fernandez F, 415
Ferrati P, 83
Ferri L, 665
Fetting JH, 409
Fiebig HH, 539
Fiere D, 571
Finberg R, 119
Finkel HE, 222
Finklestein JZ, 1033
Finn G, 220
Fiore JJ, 305, 783
Fischer DS, 1029
Fisher B, 7, 15
Flaherty MD, 1043
Fleishman G, 313, 1001
Fleming TR, 1061, 1101, 1111, 1185, 1309, 1319
Fletcher J, 1291
Fletcher WS, 985
Ford HT, 1091
Ford JM, 921
Ford L, 559
Forman SJ, 187, 645
Fornander T, 685
Foss-Abrahamsen A, 1209
Fossâ SD, 1317
Fox BW, 817
Fox RM, 1087
Fraley E, 915
Frank M, 1324
Fraschini G, 313, 1001, 1193
Fraser RC, 277, 455
Freedman RS, 327
Frei E, III, 119
Freireich EJ, 1113
Frelick RW, 559
Friedman HS, 849
Friedman MA, 557
Friess GG, 681
Frustaci S, 257, 325
Frye D, 1193
Frytak S, 211, 747, 843
Fuchs R, 1203
Fukada M, 341
Furlong EA, 1043
Furusawa S, 441
Furuta T, 341
Fusco V, 1311

G

Gabrilove JL, 39
Gail MH, 895
Galindo A, 1067
Gall HE, 1231
Galligioni E, 325, 1221
Galton DAG, 161
Gandara D, 283
Garnick MB, 97
Garrison J, 433
Gasparini G, 325, 1221
Gasper OR, 651
Gastrointestinal Tumor Study Group, 865
Gaynon PS, 1033, 1039
Gazdar AF, 697
Gazet J-C, 1091
Gebbia N, 529
Gebbia V, 529
Geller N, 887
Gelman RS, 907
George C, 845
Gershenson D, 547
Gessula J, 39
Ghosn M, 1103
Giaccone G, 83
Giannone L, 759
Gill P, 187
Ginsberg S, 1049
Girón CG, 851
Gisselbrecht C, 845
Glas U, 685
Glick JH, 215, 807
Glover AB, 737, 959
Gockerman JP, 773
Golbey R, 197
Goldenberg GJ, 901
Goldie JH, 673
Goldman ID, 581
Goldman JM, 161
Golomb HM, 179, 311
Goodwin JW, 99, 985
Gordon RA, 61
Goren MP, 87, 127, 1124
Gorgone B, 119
Gottleib RJ, 61
Grafton C, 1109
Graham SD, 89
Gralla RJ, 763, 783
Grant CE, 651
Grazia G, 855
Graziano S, 1049
Greco FA, 431
Green AA, 131
Green MD, 253, 775, 821, 877
Green MR, 533, 1049
Greenberg DB, 549
Greenwald ES, 253
Greggi S, 669
Grem JL, 1122, 1179, 1249
Grever MR, 713
Grieshaber CK, 1157
Griffing GT, 222
Griffiths JD, 1279
Grimaldi A, 485
Grimová J, 1089
Grochow LB, 53, 1171
Groppe C, 643
Grossberg H, 215
Grotto P, 525

Grunberg SM, 1097
Gucalp R, 1324
Guérin JC, 205
Gulisano M, 1311
Gumas L, 331
Gumbart CN, 713
Gundersen S, 997
Gutin PH, 459
Guyotat D, 571

H

Haas CD, 1217
Hacker D, 99
Hagemeister FB, 631
Hahn RG, 333
Haid M, 649
Hakes TB, 535, 1289
Haller DG, 907
Hamilton JM, 1249
Hammond GD, 1033, 1039
Hancock K, 1275
Hannigan JF, 969
Hanson J, 67
Hanson KH, 1095
Harker G, 1309
Harousseau JL, 991
Harris JE, 165
Harris MG, 1279
Hart RD, 615
Hartshorn JN, 141
Harvey C, 1107
Harvey HA, 61
Harvey JH, Jr, 91, 615
Harvey VJ, 335
Harvey WH, 681, 1111, 1319
Harwood KV, 103
Hasuda K, 247
Haugh LD, 141
Havsteen H, 1285
Hayashi K, 639
Hayat M, 991
Hayes FA, 131
Head D, 713
Heckard R, 61
Hedenus M, 1209
Hedley D, 1087
Heelan RT, 305, 329, 763, 783
Hendrickson C, 969
Henkelman MS, 1021
Henner WD, 119, 1043
Henson D, 559
Henss H, 539
Herait P, 1301
Heritier F, 845
Hermans J, 1267
Herrmann RP, 1279
Herzig GP, 183
Hesketh PJ, 222
Hicks W, 323
Hidalgo R, 550
Higby DJ, 433
Hill DL, 1135
Hill JH, 321
Hill RS, 101
Hillcoat BL, 191, 1007
Hillen H, 1151
Hiponia D, 861, 1099
Hirte W, 1109
Ho WG, 881
Hoeltgen T, 649, 765, 871
Hoffman PC, 311
Hoffman R, 649
Hoffman SL, 61
Hoffmann JK, 651
Holden SA, 173
Holdrinet A, 1151
Hollander P, 887
Holmes FA, 1193
Holmes VF, 415
Holoye PY, 431, 859
Holroyde CP, 875
Holt RW, 788
Holthuis JJM, 599
Homesley HD, 1295
Hong WK, 425
Hoogendoorn G, 1151
Horn Y, 605
Hornedo J, 861
Horning SJ, 475, 659
Horowitz ME, 127, 131
Hortobagyi GN, 313, 411, 777, 1001, 1193
Horwich A, 655, 785
Hoshi A, 567
Host H, 15
Hoth DF, 71, 517, 737, 1249
Hou B-S, 1013
Houghton JA, 717
Houghton PJ, 717
Howell SB, 297, 447, 705
Hrushesky WJM, 915, 1321
Hryniuk WM, 1125
Huberman MS, 201
Hug V, 1193
Huijgens PC, 552
Hulshoff A, 599
Hunter CP, 559
Hurteloup P, 991
Hutcheon A, 1197
Hynes HE, 543

I

Iacobelli S, 669
Ibrahim N, 979
Iigo M, 567
Irisson M, 205
Irvin CG, 927
Irwin L, 89
Itri LM, 747, 1097

J

Jackson DV, 151
Jacobs C, 475, 659
Jacobs RH, 311

Jaffe EA, 1067
Jaffe N, 421
Jaffe ND, 317
Jalón JI, 851
James WD, 668
Jaubert J, 991
Jeal PN, 191
Jeannin L, 205
Jefferies JA, 199
Johansen H, 7
Johnson C, 649, 765, 871
Johnson FD, 427
Johnson K, 1307
Johnson PJ, 1213
Johnston RJ, 1265
Jolis L, 550
Jones AC, 913
Jones LA, 327
Jones WG, 1317

K

Kaae S, 7
Kai H, 235
Kalra J, 317
Kamen BA, 87
Kaneda N, 341
Kanfer EJ, 101
Kaplan BH, 253
Kaplan RS, 541
Kaplan W, 119
Karanes C, 713
Karlsson A, 31
Kastello MD, 1157
Katterhagen JG, 1319
Kau S, 411
Kaufman D, 1324
Kaufman RJ, 1289
Kavanagh J, 349
Kavanagh JJ, 537, 547
Kay BG, 317
Kaye S, 1197
Keating MJ, 479, 1113
Keen C, 1197
Keller AM, 137, 331
Kelsen DP, 305, 329, 763, 783, 857
Kemeny N, 663
Kenney P, 983
Kessler JF, 391, 493
Khandekar J, 649
Kies MS, 331
Kilton L, 765, 871
Kim S, 447, 705
Kimura I, 639
King SA, 517, 1249
Kirk ME, 277, 455
Kish J, 723
Kitamura M, 1053
Klee M, 539
Klein I, 1231
Klijn JGM, 1021, 1293, 1317
Klimo P, 981
Kline RC, 327
Knight RK, 1107
Knop RH, 871
Knospe WH, 137
Knowling M, 1109
Kobrinsky NL, 1189
Kocha W, 1119
Koeller J, 965
Kohler M, 427, 767, 969
Kopecky KJ, 713, 985
Kovach JS, 489
Krakoff IH, 425, 1165
Krakoff IR, 141, 349
Kramer BS, 431
Krance RA, 645
Krasnow SH, 651
Krauss S, 649, 765
Kreisman H, 1049
Krepart GV, 277, 455
Krim M, 39
Kris MG, 763, 783
Kritharides L, 1323
Krivit W, 1039
Krook JE, 199
Krown SE, 39
Kruskall MS, 119
Kuroiwa T, 247
Kvols LK, 331, 333

L

Lad TE, 321
Lam H-YP, 901
Lamberts SWJ, 1021
Landolfi R, 751
Landys K, 1209
Lange P, 915
Langenhuijsen MMAC, 552
Langevin TR, 915
Larmon SS, 222
Larrimer NR, 1095
Latief T, 627
Laubenstein L, 775
Laucius JF, 875
Laurie JA, 429
Lawrie K, 1323
Lawton F, 627
Lazar G, 187
Lazarus HM, 689
Le Caer H, 205
Le Prise PY, 991
Le Rol A, 845
Leclerc Y, 921
Lee EJ, 755, 879
Lee JS, 859
Lee RE, 895
Leeflang P, 1267
Legha SS, 349, 1165
Leiby JM, 323
Leichman CG, 1217
Lenhard RE, Jr, 807
Lenner P, 1209
Leone G, 751
Leto G, 529
Levi JA, 273, 1087
Levin L, 455, 1119

Levin VA, 459, 1105
Levine AM, 187
Levitt M, 277
Levy A, 1029
Lew M, 119
Lewis BJ, 475, 659
Leyland-Jones BR, 71, 517, 668, 737, 959, 1249
Leyvraz S, 81
Li D-J, 1013
Licht JD, 97
Lichtiger B, 411
Lillis PK, 965
Lipperman R, 663
Lippman SM, 391, 493
Lipton A, 61
Lissoni P, 665
Løber J, 1315
Lo Re G, 257, 325
Locker GY, 649, 765, 871
Loeffler M, 1203
Loehrer PJ, Sr, 431, 1115
Logan DM, 1322
Lokich JJ, 201
Long HJ, 199, 211, 593, 747, 843
Longnecker SM, 53, 1171
Longo DL, 104
Lorusso V, 790
Lowenthal RM, 1279
Luikart SD, 533
Luks E, 1245
Lumanglas AL, 831
Lundberg WB, 1029
Lundqvist G, 31
Lusch CJ, 219
Lyman GH, 309
Lythgoe JP, 7, 15

M

MacCormick R, 941
Macdonald JS, 91, 433, 1185
MacDonald RN, 67, 635, 787, 953, 1121
Macfarlane D, 559
Madon E, 855
Maekawa S, 1053
Magid D, 179
Magill GB, 305, 329, 657
Magnusson A, 31
Maksymiuk A, 1109, 1297
Malik STA, 1291
Maloney T, 643
Mamytbeková A, 1089
Mancuso S, 669
Mango G, 751
Manoharan A, 1279
Mansour EG, 907
Maral J, 845
Marantz A, 419
Marcus RE, 161
Marcus SG, 965
Margarino G, 485
Margolese R, 921
Margolis D, 1325
Marks LD, 763, 783
Maroun JA, 1297
Marra R, 751
Marshall ME, 91, 433
Marsoni S, 71
Marty M, 845
Mason-Liddil N, 267
Mastrangelo MJ, 219, 465
Mather FJ, 609
Matsuzaki K, 235
Mattes RD, 1071
Matthews JP, 1007
Mayer RJ, 879
Mazza JJ, 137
McCaffrey RP, 222
McCarthy K, 425
McClay EF, 219, 465
McCormack GW, 199
McCormack JJ, 141
McCredie KB, 1113
McCulloch PB, 771
McDermot RSR, 1322
McDermott DF, 1067
McGehee R, 1295
McGuire WP, 471
McLaughlin P, 631
McNamara M, 765
McWhirter K, 969
Meijers WH, 155
Melby JC, 222
Melia WM, 1213
Meloy JH, 61
Mendelsohn L, 91
Merlano M, 485
Messeih AA, 61
Metch B, 723, 1313
Meulenberg P, 1151
Meyer WH, 131, 717
Meyskens FL, Jr, 391, 493
Mian AM, 441
Michaud G, 845
Michaud M, 635, 1121
Michelson S, 1093
Mick R, 1117
Miller B, 283
Miller DR, 1033
Miller FR, 317
Miller KB, 1325
Mills G, 1309
Mini E, 381
Mintzer DM, 39, 857
Mirro J, Jr, 1299
Mitchell CD, 1277
Mittelman A, 261, 657
Miyasaka T, 341
Modeas CR, 533
Modenesi M, 485
Moel D, 1039
Moertel CG, 333, 489, 593
Molineux G, 837
Monconduit M, 991
Mondora A, 1245
Monfardini S, 257, 325
Monroe S, 283
Moore MR, 89
Moroson BA, 381

Morton C, 1007
Morton RF, 429
Motzer RJ, 197
Mould GP, 813
Mould J, 627
Mouridsen HT, 987, 1315
Muggia FM, 1, 215, 253, 775, 821, 877
Mulder NH, 155, 599
Murashima M, 639
Murphy SB, 1299
Murphy WK, 859
Murray N, 1283
Muss HB, 217, 873

N

Nademanee A, 187
Nagase M, 825
Nagata H, 341
Nagourney RA, 1239
Nakajima T, 825
Natale RB, 1309
Nathan KA, 317
Natsuda Y, 235
Nazeravich DR, 1189
Neely S, 187
Neidhart JA, 323, 425, 643
Neilan BA, 643, 779
Nelimark RA, 429
Neubauer RH, 1141
Neville AJ, 575
Newland AC, 161
Newman RA, 141, 1165
Ng PKT, 901
Nichols CR, 1115
Niedzwiecki D, 39
Nierenburg M, 927
Nisselbaum J, 887
Noker PE, 1135
Nomura T, 825
Noppa H, 1209
Nosenzo M, 1311
Notake K, 341
Nowak B, 479
Nygaard SD, 1321

O

O'Bryan RM, 643, 1307
O'Connell G, 455
O'Connell MJ, 137, 333, 489
O'Donnell MR, 187
O'Dwyer PJ, 517
Öberg K, 31
Ohnoshi T, 639
Oie HK, 697
Oishi N, 1111, 1307, 1309
Oken MM, 137, 165, 807
Opfell R, 215
Ophir R, 241
Oratz R, 877
Ordóñez A, 851
Osborne RJ, 335, 417
Ossenkoppele GJ, 552
Otter GM, 727

P

Pack R, 973
Pagano L, 751
Pairolero PC, 895
Pallestrini E, 485
Panasci L, 921
Panici PB, 669
Paolorossi F, 665
Paolucci G, 525, 855
Paramelle B, 205
Participating Community Clinical Oncology Program Investigators, 171
Pasmantier MW, 1067
Pastore G, 525
Pastorino G, 1311
Pater JL, 277
Patt YZ, 313
Paul SD, 201
Pazdur R, 1217
Peckman MJ, 655
Pedersen L, 1315
Perilongo G, 525
Perrault DJ, 1322
Perry DJ, 1117
Perry MC, 533
Peters FTM, 992
Peters WP, 119
Petersen FB, 101
Peterson BA, 879
Peto R, 7, 15
Petrelli NJ, 1122
Peukert M, 93, 209, 539
Pezzoni G, 367
Pflüger KH, 1203
Pfreundschuh MG, 1203
Phillips DF, 201
Phillips GL, 183
Physicians from the Community Clinical Oncology Program, 663
Pianca C, 525
Pinedo HM, 1231
Piot G, 1301
Planting AST, 1293
Plunkett W, 479
Poplin E, 291
Portlock CS, 1029
Posner MR, 975
Possinger K, 209
Postmus PE, 155, 599
Powell BL, 151
Powis G, 593
Prados MD, 459, 1105
Pratesi G, 367
Pratt CB, 87, 127, 131, 421, 1124, 1299
Prescott RJ, 7
Presgrave P, 1087
Pronzato P, 1311
Propert KJ, 533, 1049
Pui C-H, 1299
Purl S, 311

Q

Quagliana J, 643, 1307
Queisser W, 93, 209, 539
Quirt I, 1109

R

Rabaa MS, 689
Raber MN, 349, 1165
Ragab AH, 87
Raghavan D, 191, 273
Raney M, 309, 1271
Raney, RB, Jr, 407
Rankin EM, 1107
Rasmussen F, 1285
Ratain MJ, 935
Raucheisen ML, 651
Rausa L, 529
Raymond V, 535, 657, 1289
Rayner H, 1291
Reaman GH, 1033
Reed MD, 689
Reichman B, 663
Reiffers J, 991
Reijneke RMR, 552
Reisel H, 649
Relyveld EH, 241
Remick SC, 575
Reynolds JR, 317
Řežábek K, 1089
Ribeiro G, 15
Ricci JA, 61
Richards F, 151, 1049
Richardson MG, 786
Richardson RL, 199, 781
Rigal-Huguet F, 991
Rinehart JJ, 723, 983
Ring S, 1165
Rivkin SE, 1307
Ro J, 777
Roach RW, 323
Roberts JA, 1295
Roberts JD, 141
Roberts WS, 537, 547
Robinson MH, 913
Rockwell S, 927
Rodriguez L, 1105
Roegel E, 205
Roemeling RV, 915
Rohrbaugh T, 1277
Romito S, 790
Rooney KF, 1279
Rosen F, 297
Rosenberg SA, 475, 659
Rosenbluth R, 171
Rosenstock J, 1277
Ross E, 1325
Rossi C, 1221
Rosso R, 485, 1311
Rostom AY, 813
Rougier P, 1301
Rovini D, 375
Rowinsky EK, 103, 471, 1171
Rowland C, 1197
Roy M, 277
Rozenberg MC, 1279
Ruane M, 971
Ruben RL, 1141
Rubens RD, 1107
Rubin J, 333, 489
Rubio D, 550
Ruckdeschel JC, 165, 697
Ruffie P, 1301
Runowicz C, 1324
Russell EK, 697
Russo A, 529
Ruszala-Mallon VM, 831
Rutqvist LE, 685
Ruud C, 895
Ryan DH, 713

S

Saab GA, 979
Sabbath K, 975
Saiers JH, 207, 1111, 1305, 1307, 1313
Saijo N, 567
Sainati L, 855
Sakurai M, 567
Salem HHH, 1279
Salvadori B, 375
Samuels BL, 971
Santelli A, 485
Sartain P, 87
Sather HN, 1033
Savary M, 81
Sawada S, 341
Scala M, 485
Scambia G, 669
Scarffe JH, 817, 1265
Scasso F, 485
Schaid DJ, 769, 781
Scharfman W, 137
Schein PS, 419
Scher HI, 887
Scheurlen H, 15
Schiffer CA, 879
Schiller JH, 945
Schilsky RL, 179
Schmid FA, 727
Schnetzer G, III, 215
Schnipper L, 119
Schofield R, 837
Schold SC, Jr, 849
Schoppe WD, 1203
Schryber S, 119
Schuller DE, 723
Schulman P, 755
Schutt AJ, 593, 769
Schwarz M, 273
Schweitzer JM, 61
Scott K, 1007
Seager M, 459, 1105
Seargeant LE, 1189
Sebban C, 571
Serbin J, 875

Setyono-Han B, 1021
Shapiro M, 434
Shah A, 1283
Shea TC, 119, 1043
Sheidler VR, 409
Shelley WE, 277, 455, 981
Shepherd FA, 941
Shepherd JH, 335
Sherman RL, 1067
Sherwin SA, 211, 843
Shetty MR, 785
Shevrin DE, 321
Shibata HR, 771
Shildt RA, 1101
Shoemaker DD, 1122
Shope ES, 61
Shulman HM, 101
Shurgot B, 39
Siegel SE, 1039
Silber R, 137
Silberman H, 773
Silva J, 831
Silver P, 459, 1105
Silverstein MN, 807
Silvestrini R, 375
Simmonds MA, 61
Simon KJ, 1179
Simon MA, 971
Simon RM, 3, 71, 609, 1079
Simson IW, 545
Sinkule J, 311
Sirotnak FM, 727
Skinner HA, 434
Slavik M, 99, 207, 985, 1305
Slayton RE, 661, 869, 1303
Sleijfer DT, 155, 599
Slevin ML, 335, 417, 1291
Slocombe G, 161
Smart CR, 559
Smith AC, 1157
Smith DB, 817, 1197, 1265
Smith FP, 419
Smith K, 1275
Smith LR, 151
Smith SR, 1227
Smithson WA, 747
Snyder DS, 187
Snyder R, 273
Soble M, 267
Solid Tumor Autologous Bone Marrow Team, 119
Sonneborn HA, 201
Sordillo PB, 657
Speyer JL, 877
Spiegel R, 331
Spiers A, 137
Spitzer TR, 689
Staszweski H, 755
Stedham MA, 1157
Stefanek ME, 409
Stein J, 419
Steinherz L, 1245
Steinherz P, 1245
Steinherz PG, 1033
Stephens RL, 207, 1307
Sternberg CN, 657
Stevens C, 331
Steward WP, 817
Stewart H, 7, 15
Stewart JA, 141
Stewart P, 101
Stockdale AD, 813
Stone MD, 786
Storb R, 101
Storer B, 945
Storti S, 751
Stoter G, 1293
Stroyer I, 1285
Stryker JA, 61
Stuckey WJ, 1095
Su Y-Z, 619, 1239
Subar M, 821
Suffness M, 517
Sugimachi K, 235, 1053
Sulkes A, 229
Surman OS, 549
Sus CJ, 1189
Svobodová J, 1089
Swaminathan S, 1179
Swenerton K, 455
Sylvester R, 1317

T

Tada A, 639
Taetle R, 297
Tamaro P, 525
Tan CTC, 1245
Tan Y-O, 969
Tancini G, 665
Taniguchi S, 247
Tattersall MH, 273, 1087
Tauer K, 197
Taylor KM, 434
Taylor RF, 615
Taylor SA, 1313
Tchekmedyian NS, 541
Teicher BA, 173
ten Bokkel Huinink WW, 992
Territo M, 187
Testa NG, 837
Thatcher N, 817
Theodore C, 1103, 1301
Thomas ED, 101
Thompson B, 291
Thompson EI, 131
Thomson D, 273
Thongprasert S, 95
Tilchen EJ, 1309
Tirelli U, 325
Toffoli G, 1221
Tormey DC, 907, 1179
Torti FM, 427, 767
Tranum BL, 99, 643, 985
Treille-Ritouet D, 571
Triozzi PL, 983
Trump DL, 165, 331, 989, 1179
Tseng A, Jr, 475, 659
Tsiatis AA, 807
Tumminello FM, 529

Tumulo S, 257
Tutsch KD, 1179
Tuttle RL, 165
Tyrrell C, 1197

U

Ueno K, 639
Ueoka H, 639
Uges DRA, 155
Umsawasdi T, 859

V

Valagussa P, 375
Van Damme J, 1185
van de Grampel JC, 155
van den Bosch N, 1267
van der Meulen JD, 155
van der Schoot P, 1021
van der Vijgh WJF, 1231
van der Weide M, 552
Van Echo DA, 541, 861, 1099, 1117
van Eys J, 973
van Oort WWJ, 599
van Strijen E, 1267
van Turnhout J, 1151
Vance R, 99
Varigos GA, 1323
Veeder MH, 429
Velasquez WS, 631
Venditti J, 297
Ventura GJ, 411
Verhulst M, 1151
Verleun H, 599
Vermorken JB, 1231
Verweij J, 1293
Vezin R, 817
Viala J-J, 571
Viallat JR, 205
Vinciguerra V, 329
Vogel CL, 1271
Vogelzang NJ, 935, 971
Vogl SE, 989
Vogler WR, 309
Volpe R, 1221
von Bültzingslöwen F, 539
von der Maase H, 1285
Von Hoff DD, 543, 609, 965, 1111, 1313, 1319
Vorobiof DA, 545
Vukelja SJ, 668
Vuvan H, 571

W

Wadler S, 821
Wagner H, 209
Wagstaff J, 817, 1265
Walach N, 605
Walker BK, 61
Wallach SR, 201
Wallgren A, 15
Wampler GL, 581
Wander H-E, 93
Wang BS, 831
Warr JR, 353
Warrell RP, Jr, 47
Watson R, 627
Weber E, 361
Webster DJT, 1197
Weick JK, 713
Weiden PL, 733
Weinlick A, 787
Weinstein SH, 1123
Weisenthal LM, 619, 1239
Weiss GB, 1313
Weiss RB, 668
Weitberg AB, 975
Wernz JC, 253, 775, 877
Wertenbaker C, 221
Wharton JT, 537
Wheelock J, 1275
Whisnant JK, 165
Whitacre M, 291
White D, 981
White DR, 151
White DS, 61
White LA, Jr, 1095
Wide L, 31
Wiemann MC, 975
Wiernik PH, 821, 1324
Wijermans PW, 552
Wijngaarden MJ, 552
Wilander E, 31
Wilbur B, 283
Wilcosky T, 419
Wilimas JA, 131
Willan AR, 277, 981
Willemse PHA, 155
Williams CJ, 335, 1197
Williams R, 1213
Williams RD, 767
Williams SD, 863, 1115
Willson JKV, 575, 945, 1179
Wilmore D, 119
Wilson CB, 459
Wilson KS, 277, 981
Winick N, 87
Wittes RE, 71, 107, 795
Wolf MM, 1007, 1279
Wolff SN, 183, 759
Wolter J, 649
Wong A, 749
Wong C-M, 901
Wood PA, 915
Woodroffe CM, 1227
Woodruff RE, 1279
Woods RL, 191, 273, 1087
Woolley PV, 419
Wright RK, 127
Wrigley PFM, 417

Y

Yagoda A, 887
Yamane T, 639

Yancik R, 559
Yap H-Y, 313
Yates JW, 559
Yau JC, 941
Yazigi R, 873
Yokokura T, 341
Yordan E, 873
Yoshida M, 639
Young CW, 657
Young D, 983
Young JA, 141
Young VP, 771
Yuen K, 1007

Z

Zbinden G, 361
Ziogas V, 273
Zipoli TE, 201
Zunino F, 367